1
|
Liu Y, Zhang J, Liu W, Pan Y, Ruan S, Nian X, Chen W, Sun L, Yin Q, Yue X, Li Q, Gui F, Wu C, Wang S, Yang Y, Jing Z, Long F, Wang Z, Zhang Z, Huang C, Duan K, Liang M, Yang X. Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China. Emerg Microbes Infect 2024; 13:2284297. [PMID: 37970736 DOI: 10.1080/22221751.2023.2284297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2023] [Accepted: 11/13/2023] [Indexed: 11/17/2023]
Abstract
Following the national dynamic zero-COVID strategy adjustment, the utilization of broad-spectrum nasal neutralizing antibodies may offer an alternative approach to controlling the outbreak of Omicron variants between late 2022 and early 2023 in China. This study involved an investigator-initiated trial (IIT) to assess the pharmacokinetic, safety and efficacy of the F61 nasal spray. A total of 2,008 participants were randomly assigned to receive F61 nasal spray (24 mg/0.8 mL/dose) or normal saline (0.8 mL/dose) and 1336 completed the follow-up in the IIT. Minimal absorption of F61 antibody into the bloodstream was detected in individuals receiving F61 nasal spray for seven consecutive days. No treatment-emergent adverse reactions of grade 3 severity or higher were reported. In the one-dose cohort, the 7-day cumulative SARS-CoV-2 infection rate was 79.0% in the F61 group and 82.6% in the placebo group, whereas, in the multiple-dose (once daily for 7 consecutive days) cohort, the rates were 6.55% in the F61 group and 23.83% in the placebo group. The laboratory-confirmed efficacy of F61 was 3.78% (-3.74%-10.75%) in the one-dose cohort and 72.19% (57.33%-81.87%) in the multiple-dose cohort. In the real-world study, 60,225 volunteers in four different regions were administered the F61 nasal spray based on the subject's wishes, over 90% efficacy rate was observed against different Omicron variants. The F61 nasal spray, with its favourable safety profile, could be a promising prophylactic monoclonal antibody against SARS-CoV-2 VOCs.
Collapse
Affiliation(s)
- Ying Liu
- Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People's Republic of China
- Hubei Clinical Research Center for Infectious Diseases, Wuhan, People's Republic of China
- Hubei Public Health Clinical Center, Wuhan, People's Republic of China
- Wuhan Research Center for Communicable Disease Diagnosis and Treatment, Wuhan, People's Republic of China
| | - Jiayou Zhang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, People's Republic of China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China
| | - Wen Liu
- Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People's Republic of China
- Hubei Clinical Research Center for Infectious Diseases, Wuhan, People's Republic of China
- Hubei Public Health Clinical Center, Wuhan, People's Republic of China
| | - Yongbing Pan
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, People's Republic of China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China
| | - Shunan Ruan
- Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People's Republic of China
- Hubei Clinical Research Center for Infectious Diseases, Wuhan, People's Republic of China
| | - Xuanxuan Nian
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, People's Republic of China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China
| | - Wei Chen
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, People's Republic of China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China
| | - Lina Sun
- National Institute for Viral Disease Control and Prevention, Chinese CDC, Beijing, People's Republic of China
| | - Qiangling Yin
- National Institute for Viral Disease Control and Prevention, Chinese CDC, Beijing, People's Republic of China
- Hubei Provincial Center for Disease Control and Prevention, Wuhan, People's Republic of China
| | - Xin Yue
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, People's Republic of China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China
| | - Qingliang Li
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, People's Republic of China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China
| | - Fang Gui
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, People's Republic of China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China
| | - Cong Wu
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, People's Republic of China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China
| | - Shuzhen Wang
- Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People's Republic of China
- Hubei Clinical Research Center for Infectious Diseases, Wuhan, People's Republic of China
| | - Yunkai Yang
- China National Biotec Group Company Limited, Beijing, People's Republic of China
| | - Zhaofei Jing
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, People's Republic of China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China
| | - Feiguang Long
- China National Biotec Group Company Limited, Beijing, People's Republic of China
| | - Zejun Wang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, People's Republic of China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China
| | - Zeyu Zhang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, People's Republic of China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China
| | - Chaolin Huang
- Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People's Republic of China
- Hubei Clinical Research Center for Infectious Diseases, Wuhan, People's Republic of China
- Hubei Public Health Clinical Center, Wuhan, People's Republic of China
- Wuhan Research Center for Communicable Disease Diagnosis and Treatment, Wuhan, People's Republic of China
| | - Kai Duan
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, People's Republic of China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China
| | - Mifang Liang
- National Institute for Viral Disease Control and Prevention, Chinese CDC, Beijing, People's Republic of China
| | - Xiaoming Yang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, People's Republic of China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China
- China National Biotec Group Company Limited, Beijing, People's Republic of China
| |
Collapse
|
2
|
Wang X, Pu F, Yang X, Feng X, Zhang J, Duan K, Nian X, Ma Z, Ma XX, Yang XM. Immunosuppressants exert antiviral effects against influenza A(H1N1)pdm09 virus via inhibition of nucleic acid synthesis, mRNA splicing, and protein stability. Virulence 2024; 15:2301242. [PMID: 38170681 PMCID: PMC10854267 DOI: 10.1080/21505594.2023.2301242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2023] [Accepted: 12/28/2023] [Indexed: 01/05/2024] Open
Abstract
Influenza A virus (IAV) poses a threat to patients receiving immunosuppressive medications since they are more susceptible to infection with severe symptoms, and even death. Understanding the direct effects of immunosuppressants on IAV infection is critical for optimizing immunosuppression in these patients who are infected or at risk of influenza virus infection. We profiled the effects of 10 immunosuppressants, explored the antiviral mechanisms of immunosuppressants, and demonstrated the combined effects of immunosuppressants with the antiviral drug oseltamivir in IAV-infected cell models. We found that mycophenolic acid (MPA) strongly inhibits viral RNA replication via depleting cellular guanosine pool. Treatment with 6-Thioguanine (6-TG) promoted viral protein degradation through a proteasomal pathway. Filgotinib blocked mRNA splicing of matrix protein 2, resulting in decreased viral particle assembly. Furthermore, combined treatment with immunosuppressants and oseltamivir inhibits IAV viral particle production in an additive or synergic manner. Our results suggest that MPA, 6-TG, and filgotinib could be the preferential choices for patients who must take immunosuppressants but are at risk of influenza virus infection.
Collapse
Affiliation(s)
- Xin Wang
- Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, China
- School of Stomatology, Lanzhou University, Lanzhou, China
| | - Feiyang Pu
- Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, China
| | - Xuanye Yang
- Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, China
| | - Xili Feng
- Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, China
| | - Jiayou Zhang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
- Wuhan Institute of Biological Products Co, Ltd, Wuhan, China
| | - Kai Duan
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
- Wuhan Institute of Biological Products Co, Ltd, Wuhan, China
| | - Xuanxuan Nian
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
- Wuhan Institute of Biological Products Co, Ltd, Wuhan, China
| | - Zhongren Ma
- Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, China
| | - Xiao-Xia Ma
- Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, China
| | - Xiao-Ming Yang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
- China National Biotech Group Company Limited, Beijing, China
| |
Collapse
|
3
|
Tu T, Li Y, Duan K, Zhao T. Enhancing physically-based hydrological modeling with an ensemble of machine-learning reservoir operation modules under heavy human regulation using easily accessible data. J Environ Manage 2024; 359:121044. [PMID: 38714035 DOI: 10.1016/j.jenvman.2024.121044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Revised: 04/02/2024] [Accepted: 04/28/2024] [Indexed: 05/09/2024]
Abstract
Dams and reservoirs have significantly altered river flow dynamics worldwide. Accurately representing reservoir operations in hydrological models is crucial yet challenging. Detailed reservoir operation data is often inaccessible, leading to relying on simplified reservoir operation modules in most hydrological models. To improve the capability of hydrological models to capture flow variability influenced by reservoirs, this study proposes a hybrid hydrological modeling framework, which combines a process-based hydrological model with a machine-learning-based reservoir operation module designed to simulate runoff under reservoir operations. The reservoir operation module employs an ensemble of three machine learning models: random forest, support vector machine, and AutoGluon. These models predict reservoir outflows using precipitation and temperature data as inputs. The Soil and Water Assessment Tool (SWAT) then integrates these outflow predictions to simulate runoff. To evaluate the performance of this hybrid approach, the Xijiang Basin within the Pearl River Basin, China, is used as a case study. The results highlight the superiority of the SWAT model coupled with machine learning-based reservoir operation models compared to alternative modeling approaches. This hybrid model effectively captures peak flows and dry period runoff. The Nash-Sutcliffe Efficiency (NSE) in daily runoff simulations shows substantial improvement, ranging from 0.141 to 0.780, with corresponding enhancements in the coefficient of determination (R2) by 0.098-0.397 when compared to the original reservoir operation modules in SWAT. In comparison to parameterization techniques lacking a dedicated reservoir module, NSE enhancements range from 0.068 to 0.537, and R2 improvements range from 0.027 to 0.139. The proposed hybrid modeling approach effectively characterizes the impact of reservoir operations on river flow dynamics, leading to enhanced accuracy in runoff simulation. These findings offer valuable insights for hydrological forecasting and water resources management in regions influenced by reservoir operations.
Collapse
Affiliation(s)
- Tongbi Tu
- Center of Water Resources and Environment, School of Civil Engineering, Sun Yat-Sen University, Guangzhou, 510275, China.
| | - Yilan Li
- Center of Water Resources and Environment, School of Civil Engineering, Sun Yat-Sen University, Guangzhou, 510275, China
| | - Kai Duan
- Center of Water Resources and Environment, School of Civil Engineering, Sun Yat-Sen University, Guangzhou, 510275, China.
| | - Tongtiegang Zhao
- Center of Water Resources and Environment, School of Civil Engineering, Sun Yat-Sen University, Guangzhou, 510275, China
| |
Collapse
|
4
|
Cyr DP, Pun C, Shivji S, Mitrovic B, Duan K, Tomin R, Sari A, Brar A, Zerhouni S, Brar MS, Kennedy ED, Swallow CJ, Kirsch R, Conner JR. Tumor Budding Assessment in Colorectal Carcinoma: Normalization Revisited. Am J Surg Pathol 2024; 48:251-265. [PMID: 38108373 DOI: 10.1097/pas.0000000000002166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2023]
Abstract
Tumor budding (TB) is a powerful prognostic factor in colorectal cancer (CRC). An internationally standardized method for its assessment (International Tumor Budding Consensus Conference [ITBCC] method) has been adopted by most CRC pathology protocols. This method requires that TB counts are reported by field area (0.785 mm 2 ) rather than objective lens and a normalization factor is applied for this purpose. However, the validity of this approach is yet to be tested. We sought to validate the ITBCC method with a particular emphasis on normalization as a tool for standardization. In a cohort of 365 stage I-III CRC, both normalized and non-normalized TB were significantly associated with disease-specific survival and recurrence-free survival ( P <0.0001). Examining both 0.95 and 0.785 mm 2 field areas in a subset of patients (n=200), we found that normalization markedly overcorrects TB counts: Counts obtained in a 0.95 mm 2 hotspot field were reduced by an average of 17.5% following normalization compared with only 3.8% when counts were performed in an actual 0.785 mm 2 field. This resulted in 45 (11.3%) cases being downgraded using ITBCC grading criteria following normalization, compared with only 5 cases (1.3%, P =0.0007) downgraded when a true 0.785 mm 2 field was examined. In summary, the prognostic value of TB was retained regardless of whether TB counts in a 0.95 mm 2 field were normalized. Normalization resulted in overcorrecting TB counts with consequent downgrading of most borderline cases. This has implications for risk stratification and adjuvant treatment decisions, and suggests the need to re-evaluate the role of normalization in TB assessment.
Collapse
Affiliation(s)
- David P Cyr
- Lunenfeld-Tanenbaum Research Institute
- Institute of Medical Science
- Department of Surgery, Division of General Surgery, University of Toronto
- Department of Surgical Oncology, Princess Margaret Cancer Centre and Sinai Health System
| | - Cherry Pun
- Department of Pathology and Laboratory Medicine, Sinai Health System
- Department of Laboratory Medicine Pathobiology, University of Toronto
| | - Sameer Shivji
- Department of Pathology and Laboratory Medicine, Sinai Health System
| | - Bojana Mitrovic
- Department of Pathology and Laboratory Medicine, Health Sciences North, Sudbury, ON, Canada
| | - Kai Duan
- Department of Laboratory Medicine Pathobiology, University of Toronto
- Laboratory Medicine Program, University Health Network, Toronto
| | - Rossi Tomin
- Department of Pathology and Laboratory Medicine, Sinai Health System
| | - Aysegul Sari
- Department of Pathology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey
| | - Amanpreet Brar
- Department of Surgery, Division of General Surgery, University of Toronto
| | - Siham Zerhouni
- Department of Surgery, Division of General Surgery, University of Toronto
- Department of Surgical Oncology, Princess Margaret Cancer Centre and Sinai Health System
| | - Mantaj S Brar
- Department of Surgery, Division of General Surgery, University of Toronto
| | - Erin D Kennedy
- Department of Surgery, Division of General Surgery, University of Toronto
- Department of Surgical Oncology, Princess Margaret Cancer Centre and Sinai Health System
| | - Carol J Swallow
- Lunenfeld-Tanenbaum Research Institute
- Institute of Medical Science
- Department of Surgery, Division of General Surgery, University of Toronto
- Department of Surgical Oncology, Princess Margaret Cancer Centre and Sinai Health System
| | - Richard Kirsch
- Lunenfeld-Tanenbaum Research Institute
- Department of Pathology and Laboratory Medicine, Sinai Health System
- Department of Laboratory Medicine Pathobiology, University of Toronto
| | - James R Conner
- Lunenfeld-Tanenbaum Research Institute
- Department of Pathology and Laboratory Medicine, Sinai Health System
- Department of Laboratory Medicine Pathobiology, University of Toronto
| |
Collapse
|
5
|
Qin W, Yang J, Deng C, Ruan Q, Duan K. Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial. Diabetes Obes Metab 2024; 26:911-923. [PMID: 38016699 DOI: 10.1111/dom.15386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/16/2023] [Revised: 10/23/2023] [Accepted: 11/12/2023] [Indexed: 11/30/2023]
Abstract
AIM To explore the safety and efficacy of subcutaneous semaglutide 2.4 mg, administered once a week in non-diabetic overweight or obese individuals. METHODS A thorough search was performed of various databases including PubMed, Embase, the Cochrane Library, Web of Science, clinicaltrials.gov, CNKI and Wanfang from their inception up to April 11, 2023. Our aim was to identify randomized controlled trials (RCTs) that compared the efficacy of semaglutide administered once weekly with placebo in overweight or obese adults. Through a review of the literature, data were extracted from relevant studies and assessed for quality, and a meta-analysis was conducted using RevMan 5.4.1 software. RESULTS Six RCTs comprising 3962 overweight or obese individuals were identified. The findings indicated that, in comparison to the placebo group, semaglutide caused a significant and sustainable reduction in the percentage of body weight (BW; mean difference [MD]: -11.80% [95% confidence interval {CI} -12.93, -10.68]; P < 0.00001) as well as a decrease in absolute BW (MD: -12.2 kg [95% CI -13.3, -11.1]; P < 0.00001), body mass index (MD: -4.5 kg/m2 [95% CI -4.9, -4.1]; P < 0.00001) and waist circumference (MD:-9.4 cm [95% CI -10.1, -8.8]; P < 0.00001). Moreover, it achieved a higher proportion of patients who experienced weight loss exceeding 5%, 10%, 15% and 20%. Furthermore, semaglutide showed significant efficacy in controlling blood pressure, blood sugar levels, C-reactive protein levels, and lipid profiles. In terms of safety, the most common adverse effects following semaglutide treatment were gastrointestinal adverse reactions (risk ratio: 1.49 [95% CI 1.38, 1.60]; P < 0.00001), which were generally mild to moderate in severity and temporary. CONCLUSION In overweight or obese non-diabetic individuals, semaglutide had a remarkable and sustained weight loss effect that was well tolerated and safe.
Collapse
Affiliation(s)
- Wenhui Qin
- Department of Endocrinology and Metabolism, Jingshan Union Hospital of Huazhong University of Science and Technology, Jingmen, China
| | - Jun Yang
- Department of Endocrinology and Metabolism, Jingshan Union Hospital of Huazhong University of Science and Technology, Jingmen, China
| | - Chao Deng
- Department of Pharmacy, Jingshan Union Hospital of Huazhong University of Science and Technology, Jingmen, China
| | - Qinjuan Ruan
- Department of Pharmacy, Jingshan Union Hospital of Huazhong University of Science and Technology, Jingmen, China
| | - Kai Duan
- Department of Nephrology, Jingshan Union Hospital of Huazhong University of Science and Technology, Jingmen, China
| |
Collapse
|
6
|
Wang H, Yin P, Zheng T, Qin L, Li S, Han P, Qu X, Wen J, Ding H, Wu J, Kong T, Gao Z, Hu S, Zhao X, Cao X, Fang M, Qi J, Xi JJ, Duan K, Yang X, Zhang Z, Wang Q, Tan W, Gao GF. Publisher Correction: Rational design of a 'two-in-one' immunogen DAM drives potent immune response against mpox virus. Nat Immunol 2024; 25:373. [PMID: 38225438 DOI: 10.1038/s41590-024-01748-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2024]
Affiliation(s)
- Han Wang
- Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing, China.
- Key Laboratory of Biomechanics and Mechanobiology of Ministry of Education, School of Engineering Medicine, Beihang University, Beijing, China.
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
| | - Peng Yin
- Key Laboratory of Biomechanics and Mechanobiology of Ministry of Education, School of Engineering Medicine, Beihang University, Beijing, China
| | - Tingting Zheng
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
| | - Lanju Qin
- Department of Biological Sciences, School of life Science, Liaoning University, Shenyang, China
| | - Shihua Li
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
| | - Pu Han
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
| | - Xiao Qu
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
| | - Jun Wen
- Shanghai Junshi Biosciences, Shanghai, China
| | - Haoyi Ding
- College of Veterinary Medicine, Shanxi Agricultural University, Jinzhong, China
| | - Jiahao Wu
- College of Veterinary Medicine, Shanxi Agricultural University, Jinzhong, China
- Shanxi Academy of Advanced Research and Innovation, Taiyuan, China
| | | | - Zhengrong Gao
- Shenzhen Children's Hospital, Shenzhen, China
- Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China
| | - Songtao Hu
- Cancer Center, Faculty of Health Sciences, University of Macau, Macau SAR, China
| | - Xin Zhao
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
| | - Xiangyu Cao
- Department of Biological Sciences, School of life Science, Liaoning University, Shenyang, China
| | - Min Fang
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
| | - Jianxun Qi
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
| | - Jianzhong Jeff Xi
- Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing, China
| | - Kai Duan
- Wuhan Institute of Biological Products, Wuhan, China
| | | | | | - Qihui Wang
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
| | - Wenjie Tan
- National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.
| | - George Fu Gao
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
| |
Collapse
|
7
|
Wang H, Yin P, Zheng T, Qin L, Li S, Han P, Qu X, Wen J, Ding H, Wu J, Kong T, Gao Z, Hu S, Zhao X, Cao X, Fang M, Qi J, Xi JJ, Duan K, Yang X, Zhang Z, Wang Q, Tan W, Gao GF. Rational design of a 'two-in-one' immunogen DAM drives potent immune response against mpox virus. Nat Immunol 2024; 25:307-315. [PMID: 38182667 DOI: 10.1038/s41590-023-01715-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Accepted: 11/17/2023] [Indexed: 01/07/2024]
Abstract
The global outbreak of the mpox virus (MPXV) in 2022 highlights the urgent need for safer and more accessible new-generation vaccines. Here, we used a structure-guided multi-antigen fusion strategy to design a 'two-in-one' immunogen based on the single-chain dimeric MPXV extracellular enveloped virus antigen A35 bivalently fused with the intracellular mature virus antigen M1, called DAM. DAM preserved the natural epitope configuration of both components and showed stronger A35-specific and M1-specific antibody responses and in vivo protective efficacy against vaccinia virus (VACV) compared to co-immunization strategies. The MPXV-specific neutralizing antibodies elicited by DAM were 28 times higher than those induced by live VACV vaccine. Aluminum-adjuvanted DAM vaccines protected mice from a lethal VACV challenge with a safety profile, and pilot-scale production confirmed the high yield and purity of DAM. Thus, our study provides innovative insights and an immunogen candidate for the development of alternative vaccines against MPXV and other orthopoxviruses.
Collapse
Affiliation(s)
- Han Wang
- Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing, China.
- Key Laboratory of Biomechanics and Mechanobiology of Ministry of Education, School of Engineering Medicine, Beihang University, Beijing, China.
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
| | - Peng Yin
- Key Laboratory of Biomechanics and Mechanobiology of Ministry of Education, School of Engineering Medicine, Beihang University, Beijing, China
| | - Tingting Zheng
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
| | - Lanju Qin
- Department of Biological Sciences, School of life Science, Liaoning University, Shenyang, China
| | - Shihua Li
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
| | - Pu Han
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
| | - Xiao Qu
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
| | - Jun Wen
- Shanghai Junshi Biosciences, Shanghai, China
| | - Haoyi Ding
- College of Veterinary Medicine, Shanxi Agricultural University, Jinzhong, China
| | - Jiahao Wu
- College of Veterinary Medicine, Shanxi Agricultural University, Jinzhong, China
- Shanxi Academy of Advanced Research and Innovation, Taiyuan, China
| | | | - Zhengrong Gao
- Shenzhen Children's Hospital, Shenzhen, China
- Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China
| | - Songtao Hu
- Cancer Center, Faculty of Health Sciences, University of Macau, Macau SAR, China
| | - Xin Zhao
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
| | - Xiangyu Cao
- Department of Biological Sciences, School of life Science, Liaoning University, Shenyang, China
| | - Min Fang
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
| | - Jianxun Qi
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
| | - Jianzhong Jeff Xi
- Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing, China
| | - Kai Duan
- Wuhan Institute of Biological Products, Wuhan, China
| | | | | | - Qihui Wang
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
| | - Wenjie Tan
- National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.
| | - George Fu Gao
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
| |
Collapse
|
8
|
Nian X, Liu H, Cai M, Duan K, Yang X. Correction: Nian et al. Coping Strategies for Pertussis Resurgence. Vaccines 2023, 11, 889. Vaccines (Basel) 2024; 12:151. [PMID: 38400201 PMCID: PMC10892403 DOI: 10.3390/vaccines12020151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2023] [Accepted: 11/17/2023] [Indexed: 02/25/2024] Open
Abstract
The authors would like to make the following corrections to this published paper [...].
Collapse
Affiliation(s)
- Xuanxuan Nian
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (X.N.)
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Hongbo Liu
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (X.N.)
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Mengyao Cai
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (X.N.)
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Kai Duan
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (X.N.)
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Xiaoming Yang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (X.N.)
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
- China National Biotech Group Company Limited, Beijing 100029, China
| |
Collapse
|
9
|
She Y, Chen J, Zhou Q, Wang L, Duan K, Wang R, Qu S, Xu M, Zhao Y. Evaluating Losses from Water Scarcity and Benefits of Water Conservation Measures to Intercity Supply Chains in China. Environ Sci Technol 2024; 58:1119-1130. [PMID: 38175796 DOI: 10.1021/acs.est.3c07491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2024]
Abstract
The severe water scarcity in China poses significant economic risks to its agriculture, energy, and manufacturing sectors, which can have a cascading effect through the supply chains. Current research has assessed water scarcity losses for global countries and Chinese provinces by using the water scarcity risk (WSR) method. However, this method involves subjective functions and parameter settings, and it fails to capture the adaptive behaviors of economies to water scarcity, compromising the reliability of quantified water scarcity loss. There is a pressing need for a new method to assess losses related to water scarcity. Here, we develop an agent-based complex network model to estimate the inter-regional and intersectoral impacts of water scarcity on both cities and basins. Subsequently, we evaluate the supply chain-wide economic benefits of four different water conservation measures as stipulated by the 14th Five-Year Plan for the Construction of a Water-Saving Society. These measures include increasing the utilization rate of recycled water in water-scarce cities, reducing the national water consumption per industrial value-added, and implementing agricultural and residential water conservation measures. Results show that direct losses constitute only 9% of the total losses from water scarcity. Approximately 37% of the losses can be attributed to interregional impacts. Among the water-scarce cities, Qingdao, Lanzhou, Jinan, and Zhengzhou pose a significant threat to China's supply chains. Agricultural water conservation yields the highest amount of water savings and economic benefits, while residential water conservation provides the highest economic benefit per unit of water saved. The results provide insights into managing water scarcity, promoting cross-regional cooperation, and mitigating economic impacts.
Collapse
Affiliation(s)
- Yunlei She
- School of Management and Economics, Beijing Institute of Technology, Beijing 100084, China
- Center for Energy & Environmental Policy Research, Beijing Institute of Technology, Beijing 100084, China
| | - Jiayang Chen
- School of Management and Economics, Beijing Institute of Technology, Beijing 100084, China
- Center for Energy & Environmental Policy Research, Beijing Institute of Technology, Beijing 100084, China
| | - Qi Zhou
- School of Management and Economics, Beijing Institute of Technology, Beijing 100084, China
- Center for Energy & Environmental Policy Research, Beijing Institute of Technology, Beijing 100084, China
| | - Liping Wang
- School of Economics and Management, Zhengzhou University of Light Industry, Zhengzhou 450001, China
| | - Kai Duan
- School of Civil Engineering, Sun Yat-Sen University, Guangzhou 510275, China
- Southern Marine Science and Engineering Guangdong Laboratory (Zhuhai), Zhuhai 519082, China
| | - Ranran Wang
- Institute of Environmental Sciences (CML), Leiden University, Einsteinweg 2, Leiden 2333 CC, The Netherlands
| | - Shen Qu
- School of Management and Economics, Beijing Institute of Technology, Beijing 100084, China
- Center for Energy & Environmental Policy Research, Beijing Institute of Technology, Beijing 100084, China
| | - Ming Xu
- School of Environment, Tsinghua University, Beijing 100084, China
| | - Yong Zhao
- State Key Laboratory of Simulation and Regulation of Water Cycle in River Basin, China Institute of Water Resources and Hydropower Research, Beijing 100084, China
| |
Collapse
|
10
|
Duan K, Chow B, Tsui W, Elliot C, Sari A, Shivji S, Kirsch R, Conner JR. Impact of tissue sampling on detection of venous invasion in colorectal cancer: a prospective analysis. Histopathology 2023; 83:891-902. [PMID: 37580911 DOI: 10.1111/his.15030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2023] [Revised: 07/04/2023] [Accepted: 08/01/2023] [Indexed: 08/16/2023]
Abstract
AIMS Venous invasion (VI) is a powerful yet under-reported prognostic factor in colorectal cancer (CRC). Efforts to improve its detection have largely focused upon histological assessment, with less attention paid to tissue-sampling strategies. This study aimed to prospectively determine the number of tumour blocks required to optimise VI detection in CRC resections. In addition, the relationship between linear spiculation (LS) and extramural venous invasion (EMVI) was investigated. METHODS AND RESULTS A standardised tissue sampling protocol was developed and applied prospectively to 217 CRC resections [AJCC 8th edition, stage 1 (n = 32); stage 2 (n = 84); stage 3 (n = 87); stage 4 (n = 14); and post-neoadjuvant therapy (n = 46)]. Elastin stains were performed on all tumour blocks. VI was identified in 55% of cases (EMVI = 37%; IMVI alone = 18%). The sensitivity of VI detection increased with increasing numbers of tumour blocks submitted [one block (35%), three blocks (66%), five blocks (84%), six blocks (95%) and seven blocks (97%)]. Similar findings were observed for EMVI [one block (35%), three blocks (73%), five blocks (89%), six blocks (96%) and seven blocks (96%)]. LS was identified macroscopically in 22% of specimens. In cases where no neoadjuvant therapy had been given, EMVI was significantly associated with LS (71% in LS+ cases versus 29% in LS- cases; P < 0.001). In addition, tumour blocks targeting LS were associated with a fivefold higher rate of EMVI compared with blocks that did not (P < 0.001). CONCLUSIONS Our findings demonstrate the impact of tissue sampling and quality of gross examination on VI detection and may inform practices in future CRC protocols.
Collapse
Affiliation(s)
- Kai Duan
- Department of Pathology and Laboratory Medicine, Sinai Health System, Toronto, ON, Canada
- Department of Pathology, University Health Network, Toronto, ON, Canada
- Department of Pathobiology and Laboratory Medicine, University of Toronto, Toronto, ON, Canada
| | - Brian Chow
- Department of Pathology and Laboratory Medicine, Sinai Health System, Toronto, ON, Canada
- Department of Pathobiology and Laboratory Medicine, University of Toronto, Toronto, ON, Canada
| | - William Tsui
- Department of Pathology and Laboratory Medicine, Sinai Health System, Toronto, ON, Canada
- Department of Pathobiology and Laboratory Medicine, University of Toronto, Toronto, ON, Canada
| | - Colin Elliot
- Department of Pathology and Laboratory Medicine, Sinai Health System, Toronto, ON, Canada
| | - Aysegul Sari
- Department of Pathology and Laboratory Medicine, Sinai Health System, Toronto, ON, Canada
- Department of Pathology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey
| | - Sameer Shivji
- Department of Pathology and Laboratory Medicine, Sinai Health System, Toronto, ON, Canada
| | - Richard Kirsch
- Department of Pathology and Laboratory Medicine, Sinai Health System, Toronto, ON, Canada
- Department of Pathobiology and Laboratory Medicine, University of Toronto, Toronto, ON, Canada
- Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada
| | - James R Conner
- Department of Pathology and Laboratory Medicine, Sinai Health System, Toronto, ON, Canada
- Department of Pathobiology and Laboratory Medicine, University of Toronto, Toronto, ON, Canada
- Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada
| |
Collapse
|
11
|
Sun N, Zhang Y, Dong J, Liu G, Liu Z, Wang J, Qiao Z, Zhang J, Duan K, Nian X, Ma Z, Yang X. Metabolomics profiling reveals differences in proliferation between tumorigenic and non-tumorigenic Madin-Darby canine kidney (MDCK) cells. PeerJ 2023; 11:e16077. [PMID: 37744241 PMCID: PMC10517658 DOI: 10.7717/peerj.16077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Accepted: 08/20/2023] [Indexed: 09/26/2023] Open
Abstract
Background Madin-Darby canine kidney (MDCK) cells are a cellular matrix in the production of influenza vaccines. The proliferation rate of MDCK cells is one of the critical factors that determine the vaccine production cycle. It is yet to be determined if there is a correlation between cell proliferation and alterations in metabolic levels. This study aimed to explore the metabolic differences between MDCK cells with varying proliferative capabilities through the use of both untargeted and targeted metabolomics. Methods To investigate the metabolic discrepancies between adherent cell groups (MDCK-M60 and MDCK-CL23) and suspension cell groups (MDCK-XF04 and MDCK-XF06), untargeted and targeted metabolomics were used. Utilizing RT-qPCR analysis, the mRNA expressions of key metabolites enzymes were identified. Results An untargeted metabolomics study demonstrated the presence of 81 metabolites between MDCK-M60 and MDCK-CL23 cells, which were mainly affected by six pathways. An analysis of MDCK-XF04 and MDCK-XF06 cells revealed a total of 113 potential metabolites, the majority of which were impacted by ten pathways. Targeted metabolomics revealed a decrease in the levels of choline, tryptophan, and tyrosine in MDCK-CL23 cells, which was in accordance with the results of untargeted metabolomics. Additionally, MDCK-XF06 cells experienced a decrease in 5'-methylthioadenosine and tryptophan, while S-adenosylhomocysteine, kynurenine, 11Z-eicosenoic acid, 3-phosphoglycerate, glucose 6-phosphate, and phosphoenolpyruvic acid concentrations were increased. The mRNA levels of MAT1A, MAT2B, IDO1, and IDO2 in the two cell groups were all increased, suggesting that S-adenosylmethionine and tryptophan may have a significant role in cell metabolism. Conclusions This research examines the effect of metabolite fluctuations on cell proliferation, thus offering a potential way to improve the rate of MDCK cell growth.
Collapse
Affiliation(s)
- Na Sun
- Gansu Technology Innovation Center of Animal Cell, Biomedical Research Center, Northwest Minzu University, Lanzhou, China
- Engineering Research Center of Key Technology and Industrialization of Cell-based Vaccine, Ministry of Education, Lanzhou, China
| | - Yuchuan Zhang
- Gansu Technology Innovation Center of Animal Cell, Biomedical Research Center, Northwest Minzu University, Lanzhou, China
| | - Jian Dong
- Gansu Technology Innovation Center of Animal Cell, Biomedical Research Center, Northwest Minzu University, Lanzhou, China
| | - Geng Liu
- Gansu Technology Innovation Center of Animal Cell, Biomedical Research Center, Northwest Minzu University, Lanzhou, China
| | - Zhenbin Liu
- Gansu Technology Innovation Center of Animal Cell, Biomedical Research Center, Northwest Minzu University, Lanzhou, China
- Engineering Research Center of Key Technology and Industrialization of Cell-based Vaccine, Ministry of Education, Lanzhou, China
| | - Jiamin Wang
- Gansu Technology Innovation Center of Animal Cell, Biomedical Research Center, Northwest Minzu University, Lanzhou, China
- Engineering Research Center of Key Technology and Industrialization of Cell-based Vaccine, Ministry of Education, Lanzhou, China
- Gansu Provincial Bioengineering Materials Engineering Research Center, Lanzhou, China
| | - Zilin Qiao
- Gansu Technology Innovation Center of Animal Cell, Biomedical Research Center, Northwest Minzu University, Lanzhou, China
- Engineering Research Center of Key Technology and Industrialization of Cell-based Vaccine, Ministry of Education, Lanzhou, China
- Gansu Provincial Bioengineering Materials Engineering Research Center, Lanzhou, China
| | - Jiayou Zhang
- Wuhan Institute of Biological Products Co., Ltd., Wuhan, China
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
| | - Kai Duan
- Wuhan Institute of Biological Products Co., Ltd., Wuhan, China
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
| | - Xuanxuan Nian
- Wuhan Institute of Biological Products Co., Ltd., Wuhan, China
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
| | - Zhongren Ma
- Gansu Technology Innovation Center of Animal Cell, Biomedical Research Center, Northwest Minzu University, Lanzhou, China
- Engineering Research Center of Key Technology and Industrialization of Cell-based Vaccine, Ministry of Education, Lanzhou, China
- Key Laboratory of Biotechnology and Bioengineering of National Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, China
| | - Xiaoming Yang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
- China National Biotech Group Company Limited, Beijing, China
| |
Collapse
|
12
|
Wu ZW, Jin F, Li QL, Gao JM, Zhou HS, Duan K, Gao Z, Liu Y, Hao ZY, Chen W, Liu YY, Xu GL, Yang B, Dong B, Zhang JW, Zhao YL, Yang XM. Immunogenicity and safety of a new hexavalent rotavirus vaccine in Chinese infants: A randomized, double-blind, placebo-controlled phase 2 clinical trial. Hum Vaccin Immunother 2023; 19:2263228. [PMID: 37843437 PMCID: PMC10580834 DOI: 10.1080/21645515.2023.2263228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Accepted: 09/22/2023] [Indexed: 10/17/2023] Open
Abstract
Rotavirus remains a major cause of diarrhea among 5-y-old children, and vaccination is currently the most effective and economical measure. We conducted a randomized, double-blind, placebo-controlled phase II clinical trial designed to determine the dosage, immunogenicity, and safety profile of a novel hexavalent rotavirus vaccine. In total, 480 eligible healthy infants, who were 6-12 weeks of age at the time of randomization were randomly allocated (1:1:1) to receive 105.5 focus-forming unit (FFU) or 106.5FFU of vaccine or placebo on a 0, 28 and 56-d schedule. Blood samples were collected 28 d after the third dose to assess rotavirus immunoglobulin A (IgA) antibody levels. Adverse events (AEs) up to 28 d after each dose and serious adverse events (SAEs) up to 6 months after the third dose were recorded as safety measurements. The anti-rotavirus IgA seroconversion rate of the vaccine groups reached more than 70.00%, ranging from 74.63% to 76.87%. The postdose 3 (PD3) geometric mean concentrations (GMCs) of anti-rotavirus IgA among vaccine recipients ranged from 76.97 U/ml to 84.46 U/ml. At least one solicited AE was recorded in 114 infants (71.25%) in the high-dose vaccine group, 106 infants (66.25%) in the low-dose vaccine group and 104 infants (65.00%) in the placebo group. The most frequently solicited AE was fever. The novel oral hexavalent rotavirus vaccine was safe and immunogenic in infants support the conclusion to advance the candidate vaccine for phase 3 efficacy trials.
Collapse
Affiliation(s)
- Zhi-Wei Wu
- Institute for Vaccine Clinical Research, Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People’s Republic of China
| | - Fei Jin
- Institute for Vaccine Clinical Research, Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People’s Republic of China
| | - Qing-Liang Li
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co., Ltd, Wuhan, People’s Republic of China
| | - Jia-Mei Gao
- National Institutes for Food and Drug Control, Beijing, China
| | - Hai-Song Zhou
- Zhengding County Center for Disease Control and Prevention, Zhengding, People’s Republic of China
| | - Kai Duan
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co., Ltd, Wuhan, People’s Republic of China
| | - Zhao Gao
- Institute for Vaccine Clinical Research, Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People’s Republic of China
| | - Yan Liu
- National Institutes for Food and Drug Control, Beijing, China
| | - Zhi-Yong Hao
- Zhengding County Center for Disease Control and Prevention, Zhengding, People’s Republic of China
| | - Wei Chen
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co., Ltd, Wuhan, People’s Republic of China
| | - Yue-Yue Liu
- National Institutes for Food and Drug Control, Beijing, China
| | - Ge-Lin Xu
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co., Ltd, Wuhan, People’s Republic of China
| | - Biao Yang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co., Ltd, Wuhan, People’s Republic of China
| | - Ben Dong
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co., Ltd, Wuhan, People’s Republic of China
| | - Jiu-Wei Zhang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co., Ltd, Wuhan, People’s Republic of China
| | - Yu-Liang Zhao
- Institute for Vaccine Clinical Research, Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People’s Republic of China
| | - Xiao-Ming Yang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co., Ltd, Wuhan, People’s Republic of China
| |
Collapse
|
13
|
Liu Z, Pei M, Liu G, Qiu Z, Wang S, Qiao Z, Wang J, Jin D, Zhang J, Duan K, Nian X, Ma Z, Yang X. CDC20 is a potential target gene to inhibit the tumorigenesis of MDCK cells. Biologicals 2023; 83:101697. [PMID: 37579524 DOI: 10.1016/j.biologicals.2023.101697] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2023] [Revised: 07/05/2023] [Accepted: 08/01/2023] [Indexed: 08/16/2023] Open
Abstract
MDCK is currently the main cell line used for influenza vaccine production in culture. Previous studies have reported that MDCK cells possess tumorigenic ability in nude mice. Although complete cell lysis can be ensured during vaccine production, host cell DNA released after cell lysis may still pose a risk for tumorigenesis. Greater caution is needed in the production of human vaccines; therefore, the use of gene editing to establish cells incapable of forming tumors may significantly improve the safety of influenza vaccines. Knowledge regarding the genes and molecular mechanisms that affect the tumorigenic ability of MDCK cells is crucial; however, our understanding remains superficial. Through monoclonal cell screening, we previously obtained a cell line, CL23, that possesses significantly reduced cell proliferation, migration, and invasion abilities, and tumor-bearing experiments in nude mice showed the absence of tumorigenic cells. With a view to exploring tumorigenesis-related genes in MDCK cells, DIA proteomics was used to compare the differences in protein expression between wild-type (M60) and non-tumorigenic (CL23) cells. Differentially expressed proteins were verified at the mRNA level by RT-qPCR, and a number of genes involved in cell tumorigenesis were preliminarily screened. Immunoblotting further confirmed that related protein expression was significantly reduced in non-tumorigenic cells. Inhibition of CDC20 expression by RNAi significantly reduced the proliferation and migration of MDCK cells and increased the proliferation of the influenza virus; therefore, CDC20 was preliminarily determined to be an effective target gene for the inhibition of cell tumorigenicity. These results contribute to a more comprehensive understanding of the mechanism underlying cell tumorigenesis and provide a basis for the establishment of target gene screening in genetically engineered non-tumorigenic MDCK cell lines.
Collapse
Affiliation(s)
- Zhenbin Liu
- Engineering Research Center of Key Technology and Industrialization of Cell-based Vaccine, Ministry of Education, Lanzhou, 730030, China; Gansu Tech Innovation Center of Animal Cell, Biomedical Research Center, Northwest Minzu University Lanzhou 730030, China; Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, 730030, China
| | - Mengyuan Pei
- Engineering Research Center of Key Technology and Industrialization of Cell-based Vaccine, Ministry of Education, Lanzhou, 730030, China
| | - Geng Liu
- Engineering Research Center of Key Technology and Industrialization of Cell-based Vaccine, Ministry of Education, Lanzhou, 730030, China
| | - Zhenyu Qiu
- Engineering Research Center of Key Technology and Industrialization of Cell-based Vaccine, Ministry of Education, Lanzhou, 730030, China
| | - Siya Wang
- Engineering Research Center of Key Technology and Industrialization of Cell-based Vaccine, Ministry of Education, Lanzhou, 730030, China
| | - Zilin Qiao
- Engineering Research Center of Key Technology and Industrialization of Cell-based Vaccine, Ministry of Education, Lanzhou, 730030, China; Gansu Tech Innovation Center of Animal Cell, Biomedical Research Center, Northwest Minzu University Lanzhou 730030, China; Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, 730030, China
| | - Jiamin Wang
- Engineering Research Center of Key Technology and Industrialization of Cell-based Vaccine, Ministry of Education, Lanzhou, 730030, China; Gansu Tech Innovation Center of Animal Cell, Biomedical Research Center, Northwest Minzu University Lanzhou 730030, China; Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, 730030, China
| | - Dongwu Jin
- Gansu Provincial Bioengineering Materials Engineering Research Center, Lanzhou, 730010, China
| | - Jiayou Zhang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, 430207, China; Wuhan Institute of Biological Products Co., Ltd., Wuhan, 430207, China
| | - Kai Duan
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, 430207, China; Wuhan Institute of Biological Products Co., Ltd., Wuhan, 430207, China
| | - Xuanxuan Nian
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, 430207, China; Wuhan Institute of Biological Products Co., Ltd., Wuhan, 430207, China
| | - Zhongren Ma
- Engineering Research Center of Key Technology and Industrialization of Cell-based Vaccine, Ministry of Education, Lanzhou, 730030, China; Gansu Tech Innovation Center of Animal Cell, Biomedical Research Center, Northwest Minzu University Lanzhou 730030, China; Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, 730030, China
| | - Xiaoming Yang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, 430207, China; China National Biotech Group Company Limited, Beijing, 100029, China.
| |
Collapse
|
14
|
Azhie A, Sharma D, Sheth P, Qazi-Arisar FA, Zaya R, Naghibzadeh M, Duan K, Fischer S, Patel K, Tsien C, Selzner N, Lilly L, Jaeckel E, Xu W, Bhat M. A deep learning framework for personalised dynamic diagnosis of graft fibrosis after liver transplantation: a retrospective, single Canadian centre, longitudinal study. Lancet Digit Health 2023; 5:e458-e466. [PMID: 37210229 DOI: 10.1016/s2589-7500(23)00068-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2022] [Revised: 03/13/2023] [Accepted: 03/23/2023] [Indexed: 05/22/2023]
Abstract
BACKGROUND Recurrent graft fibrosis after liver transplantation can threaten both graft and patient survival. Therefore, early detection of fibrosis is essential to avoid disease progression and the need for retransplantation. Non-invasive blood-based biomarkers of fibrosis are limited by moderate accuracy and high cost. We aimed to evaluate the accuracy of machine learning algorithms in detecting graft fibrosis using longitudinal clinical and laboratory data. METHODS In this retrospective, longitudinal study, we trained machine learning algorithms, including our novel weighted long short-term memory (LSTM) model, to predict the risk of significant fibrosis using follow-up data from 1893 adults who had a liver transplantation between Feb 1, 1987, and Dec 30, 2019, with at least one liver biopsy post transplantation. Liver biopsy samples with indefinitive fibrosis stage and those from patients with multiple transplantations were excluded. Longitudinal clinical variables were collected from transplantation to the date of last available liver biopsy. Deep learning models were trained on 70% of the patients as the training set and 30% of the patients as the test set. The algorithms were also separately tested on longitudinal data from patients in a subgroup of patients (n=149) who had transient elastography within 1 year before or after the date of liver biopsy. Weighted LSTM model performance for diagnosing significant fibrosis was compared against LSTM, other deep learning models (recurrent neural network and temporal convolutional network), and machine learning models (Random Forest, Support vector machines, Logistic regression, Lasso regression, and Ridge regression) and aspartate aminotransferase-to-platelet ratio index (APRI), fibrosis-4 index (FIB-4), and transient elastography. FINDINGS 1893 people who had a liver transplantation (1261 [67%] men and 632 [33%] women) with at least one liver biopsy between Jan 1, 1992, and June 30, 2020, were included in the study (591 [31%] cases and 1302 [69%] controls). The median age at liver transplantation was 53·7 years (IQR 47·3-59·0) for cases and 55·3 years (48·0 to 61·2) for controls. The median time interval between transplant and liver biopsy was 21 months (5 to 71). The weighted LSTM model (area under the curve 0·798 [95% CI 0·790 to 0·810]) consistently outperformed other methods, including unweighted LSTM (0·761 [0·750 to 0·769]; p=0·031) Recurrent Neural Network (0·736 [0·721 to 0·744]), Temporal Convolutional Networks (0·700 [0·662 to 0·747], and Random Forest 0·679 [0·652 to 0·707]), FIB-4 (0·650 [0·636 to 0·663]) and APRI (0·682 [0·671 to 0·694]) when diagnosing F2 or worse stage fibrosis. In a subgroup of patients with transient elastography results, weighted LSTM was not significantly better at detecting fibrosis (≥F2; 0·705 [0·687 to 0·724]) than transient elastography (0·685 [0·662 to 0·704]). The top ten variables predictive for significant fibrosis were recipient age, primary indication for transplantation, donor age, and longitudinal data for creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, platelets, white blood cell count, and weight. INTERPRETATION Deep learning algorithms, particularly weighted LSTM, outperform other routinely used non-invasive modalities and could help with the earlier diagnosis of graft fibrosis using longitudinal clinical and laboratory variables. The list of most important predictive variables for the development of fibrosis will enable clinicians to modify their management accordingly to prevent onset of graft cirrhosis. FUNDING Canadian Institute of Health Research, American Society of Transplantation, Toronto General and Western Hospital Foundation, and Paladin Labs.
Collapse
Affiliation(s)
- Amirhossein Azhie
- Ajmera Transplant Program, University Health Network, Toronto, ON, Canada
| | - Divya Sharma
- Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - Priya Sheth
- Ajmera Transplant Program, University Health Network, Toronto, ON, Canada
| | - Fakhar Ali Qazi-Arisar
- Ajmera Transplant Program, University Health Network, Toronto, ON, Canada; Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, ON, Canada; National Institute of Liver & Gastrointestinal Diseases, Dow University of Health Sciences, Karachi, Pakistan
| | - Rita Zaya
- Ajmera Transplant Program, University Health Network, Toronto, ON, Canada
| | - Maryam Naghibzadeh
- Ajmera Transplant Program, University Health Network, Toronto, ON, Canada
| | - Kai Duan
- Department of Pathology, University Health Network, Toronto, ON, Canada
| | - Sandra Fischer
- Department of Pathology, University Health Network, Toronto, ON, Canada
| | - Keyur Patel
- Toronto Centre for Liver Disease, University Health Network, Toronto, ON, Canada; Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, ON, Canada
| | - Cynthia Tsien
- Ajmera Transplant Program, University Health Network, Toronto, ON, Canada; Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, ON, Canada
| | - Nazia Selzner
- Ajmera Transplant Program, University Health Network, Toronto, ON, Canada; Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, ON, Canada
| | - Leslie Lilly
- Ajmera Transplant Program, University Health Network, Toronto, ON, Canada; Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, ON, Canada
| | - Elmar Jaeckel
- Ajmera Transplant Program, University Health Network, Toronto, ON, Canada; Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, ON, Canada
| | - Wei Xu
- Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Biostatistics Division, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
| | - Mamatha Bhat
- Ajmera Transplant Program, University Health Network, Toronto, ON, Canada; Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
| |
Collapse
|
15
|
Zhang J, Nian X, Liu B, Zhang Z, Zhao W, Han X, Ma Y, Jin D, Ma H, Zhang Q, Qiu R, Li F, Gong Z, Li X, Yang Y, Tian Y, Zhou L, Duan K, Li X, Ma Z, Yang X. Development of MDCK-based quadrivalent split seasonal influenza virus vaccine with high safety and immunoprotection: A preclinical study. Antiviral Res 2023; 216:105639. [PMID: 37270159 DOI: 10.1016/j.antiviral.2023.105639] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2023] [Revised: 04/12/2023] [Accepted: 05/17/2023] [Indexed: 06/05/2023]
Abstract
Vaccination remains the best prevention strategy against influenza. The MDCK-based influenza vaccine prompted the development of innovative cell culture manufacturing processes. In the present study, we report the effects of multiple administrations of a candidate, seasonal, MDCK-based, quadrivalent split influenza virus vaccine MDCK-QIV in Sprague-Dawley (SD) rats. Moreover, the effects of the vaccine were evaluated in terms of fertility and early embryonic development, embryo-fetal development, and perinatal toxicity in the SD rats and immunogenicity in Wistar rats and BALB/c mice. Regarding the safety profile, MDCK-QIV demonstrated tolerance in local stimulation with repeated dose administration and presented no significant effect on the development, growth, behavior, fertility, and reproductive performance of the adult male rats, maternal rats, and their offspring. MDCK-QIV elicited strong hemagglutination inhibition neutralizing antibody response and protection against the influenza virus in the mouse model. Thus, data supported that MDCK-QIV could be further evaluated in human clinical trial, which is currently underway.
Collapse
Affiliation(s)
- Jiayou Zhang
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Xuanxuan Nian
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Bo Liu
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Zhegang Zhang
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Wei Zhao
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Xixin Han
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Yumei Ma
- Lanzhou BaiLing Biotech Co., Ltd, 730010, Lanzhou, China
| | - Dongwu Jin
- Lanzhou BaiLing Biotech Co., Ltd, 730010, Lanzhou, China
| | - Hua Ma
- Lanzhou BaiLing Biotech Co., Ltd, 730010, Lanzhou, China
| | - Qingmei Zhang
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Ran Qiu
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Fang Li
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Zheng Gong
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Xuedan Li
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Ying Yang
- Hubei Topgene Biotechnology Co., Ltd, 430074, Wuhan, China
| | - Yichao Tian
- Hubei Topgene Biotechnology Co., Ltd, 430074, Wuhan, China
| | - Li Zhou
- Hubei Topgene Biotechnology Co., Ltd, 430074, Wuhan, China
| | - Kai Duan
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Xinguo Li
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China
| | - Zhongren Ma
- Lanzhou BaiLing Biotech Co., Ltd, 730010, Lanzhou, China.
| | - Xiaoming Yang
- National Engineering Technology Research Center for Combined Vaccines, 430207, Wuhan, China; Wuhan Institute of Biological Products Co., Ltd., 430207, Wuhan, China; China National Biotec Group Company Limited, 100029, Beijing, China.
| |
Collapse
|
16
|
Huang X, Liang J, Huang L, Nian X, Chen W, Zhang J, Xu X, Lin X, Wang Y, Shi J, Jia L, Li Q, Wang Q, Duan K, Li X, Ji Y, Peng F, Zhang W, Xie Z, Wang Y, Yang X. Safety and immunogenicity of rabies vaccine (PVRV-WIBP) in healthy Chinese aged 10-50 years old: Randomized, blinded, parallel controlled phase III clinical study. Hum Vaccin Immunother 2023:2211896. [PMID: 37249318 DOI: 10.1080/21645515.2023.2211896] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023] Open
Abstract
This phase III clinical trial aimed to assess the safety and demonstrate the immunogenicity of a candidate freeze-dried purified Vero cell-based rabies vaccine (PVRV-WIBP) developed for human use. A cohort of 40 participants in stage 1 and 1956 subjects in stage 2 with an age range of 10-50 years were recruited for the phase III clinical trial. For safety analysis in stage 1, 20 participants received either 4-dose or 5-dose regimen of PVRV-WIBP. In stage 2, 1956 subjects were randomly divided into the 5-dose PVRV-WIBP, 5-dose PVRV-LNCD, and 4-dose PVRV-WIBP groups. The serum neutralizing antibody titer against rabies was determined on day 7 or 14 and day 35 or 42. Adverse reactions were recorded for more than 6 months. Most adverse reactions, which were mild and moderate in severity, occurred and resolved within 1 week after each injection in the PVRV-WIBP (4 and 5 doses) and PVRV-LNCD (5 doses) groups. All three groups achieved complete seroconversion 14 days after the initial dose and 14 days after completing the full vaccination schedule, the susceptible subjects in the PVRV-WIBP group (4-dose or 5-dose regimen) displayed higher neutralizing antibody titers against the rabies virus compared to those in the PVRV-LNCD group (5-dose regimen). PVRV-WIBP induced non-inferior immune responses versus PVRV-LNCD as assessed by seroconversion rate. PVRV-WIBP was well tolerated and non-inferior to PVRV-LNCD in healthy individuals aged 10-50 years. The results indicated that PVRV-WIBP (both 4- and 5-dose schedules) could be an alternative to rabies post-exposure prophylaxis.
Collapse
Affiliation(s)
- Xiaoyuan Huang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, China
| | - Jing Liang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, China
| | - Lili Huang
- Henan Provincial Center for Disease Control and Prevention, Zhengzhoa, China
| | - Xuanxuan Nian
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, China
| | - Wei Chen
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, China
| | - Jiayou Zhang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, China
| | - Xiao Xu
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, China
| | - Xuan Lin
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, China
| | - Yue Wang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, China
| | - Jinrong Shi
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, China
| | - Lanxin Jia
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, China
| | - Qingliang Li
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, China
| | - Qianxi Wang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, China
| | - Kai Duan
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, China
| | - Xinguo Li
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, China
| | - Yaqi Ji
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, China
| | - Feixia Peng
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, China
| | - Wei Zhang
- Henan Provincial Center for Disease Control and Prevention, Zhengzhoa, China
| | - Zhiqiang Xie
- Henan Provincial Center for Disease Control and Prevention, Zhengzhoa, China
| | - Yanxia Wang
- Henan Provincial Center for Disease Control and Prevention, Zhengzhoa, China
| | - Xiaoming Yang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
- China National Biotech Group Company Limited, Beijing, China
| |
Collapse
|
17
|
Zhang J, Qiu Z, Wang S, Liu Z, Qiao Z, Wang J, Duan K, Nian X, Ma Z, Yang X. Suspended cell lines for inactivated virus vaccine production. Expert Rev Vaccines 2023; 22:468-480. [PMID: 37199282 DOI: 10.1080/14760584.2023.2214219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/19/2023]
Abstract
INTRODUCTION Inactivated virus vaccines are the most widely used tool to prevent disease. To meet vaccine production demands, increasing attention has been placed on identifying methods to improve vaccine production efficiency. The use of suspended cells can greatly increase vaccine production. Suspension acclimation is a traditional method to convert adherent cells to suspension strains. Furthermore, as genetic engineering technology has developed, increasing attention has focused on the development of suspension cell lines using targeted genetic engineering techniques. AREAS COVERED This review systematically summarizes and analyzes the development and research progress of various inactivated viral vaccine production suspension cell lines and provides protocols and candidate target genes for the engineered establishment of additional suspension cell lines for vaccine production. EXPERT OPINION The use of suspended cells can significantly improve the production efficiency of inactivated virus vaccines and other biological products. Presently, cell suspension culture is the key component to improve many vaccine production processes.
Collapse
Affiliation(s)
- Jiayou Zhang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
| | - Zhenyu Qiu
- Gansu Tech Innovation Center of Animal Cell, Biomedical Research Center, Northwest Minzu University, Lanzhou 730030, China
| | - Siya Wang
- Gansu Tech Innovation Center of Animal Cell, Biomedical Research Center, Northwest Minzu University, Lanzhou 730030, China
| | - Zhenbin Liu
- Gansu Tech Innovation Center of Animal Cell, Biomedical Research Center, Northwest Minzu University, Lanzhou 730030, China
- Key Laboratory of Biotechnology & Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou 730030, China
| | - Ziling Qiao
- Gansu Tech Innovation Center of Animal Cell, Biomedical Research Center, Northwest Minzu University, Lanzhou 730030, China
- Key Laboratory of Biotechnology & Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou 730030, China
| | - Jiamin Wang
- Gansu Tech Innovation Center of Animal Cell, Biomedical Research Center, Northwest Minzu University, Lanzhou 730030, China
- Key Laboratory of Biotechnology & Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou 730030, China
- Lanzhou Bailing Biotechnology Co. LTD, Lanzhou 730010
| | - Kai Duan
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co. Ltd. Wuhan 430207, China
| | - Xuanxuan Nian
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co. Ltd. Wuhan 430207, China
| | - Zhongren Ma
- Gansu Tech Innovation Center of Animal Cell, Biomedical Research Center, Northwest Minzu University, Lanzhou 730030, China
- Lanzhou Bailing Biotechnology Co. LTD, Lanzhou 730010
| | - Xiaoming Yang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- China National Biotech Group Company Limited, Beijing 100029, China
| |
Collapse
|
18
|
Dobbs GR, Liu N, Caldwell PV, Miniat CF, Sun G, Duan K, Bolstad PV. Inter-basin surface water transfers database for public water supplies in conterminous United States, 1986-2015. Sci Data 2023; 10:255. [PMID: 37149676 PMCID: PMC10164180 DOI: 10.1038/s41597-023-02148-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2022] [Accepted: 04/12/2023] [Indexed: 05/08/2023] Open
Abstract
The manipulation of water resources is a common human solution to water-related problems. Of particular interest because of impacts on both source and destination is the anthropogenic movement of water from one basin to another, or inter-basin transfers (IBTs). In the United States, IBTs occur widely in both wet and dry regions, but IBT data are not collated and served in a coordinated way. Thus researchers wishing to account for transfers between basins have faced difficulty in doing so. Here we present the outcome of a systematic investigation into inter-basin surface water transfers connected with public water supplies in the conterminous United States (CONUS), 1986 to 2015. The present open-access geodatabase includes transfer volumes collected, evaluated, and compiled from disparate sources. We provide an updated snapshot of CONUS IBTs at a higher spatial resolution of points of withdrawal and delivery than previous datasets. This paper puts the national inter-basin transfer data in context, and shows how we acquired, structured, and validated the locations and volumes of surface water transfers in public water systems.
Collapse
Affiliation(s)
- G Rebecca Dobbs
- Southern Research Station, USDA Forest Service, Asheville, USA.
- Oak Ridge Institute for Science and Education, Oak Ridge, USA.
| | - Ning Liu
- Southern Research Station, USDA Forest Service, Asheville, USA
- Oak Ridge Institute for Science and Education, Oak Ridge, USA
- Commonwealth Scientific and Industrial Research Organisation - Environment, Canberra, Australia
| | | | | | - Ge Sun
- Southern Research Station, USDA Forest Service, Asheville, USA
| | - Kai Duan
- Sun Yat-sen University, Guangzhou, P. R. China
| | | |
Collapse
|
19
|
Zeng Y, Liu X, Li Y, Lu J, Wu Q, Dan D, Lv S, Xia F, Hu C, Li J, Zhang H, Du H, Jia R, Duan K, Wang Z, Li X, Yang X. The assessment on cross immunity with smallpox virus and antiviral drug sensitivity of the isolated mpox virus strain WIBP-MPXV-001 in China. Emerg Microbes Infect 2023; 12:2208682. [PMID: 37128898 PMCID: PMC10177700 DOI: 10.1080/22221751.2023.2208682] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
Since May 2022, human mpox cases have increased unexpectedly in non-endemic countries. The first imported case of human mpox in Hong Kong was reported in September 2022. Here we report the isolation and identification of MPXV from the vesicle swabs of this patient. In this research, the vesicle swabs were inoculated in Vero and Vero E6 cells. In addition to observing cytopathic effects (CPEs) in Vero or Vero E6 cells, the isolated virus was identified as mpox virus (MPXV) using quantitative Real-Time PCR (RT-PCR), transmission electron microscopy, and high-throughput sequencing. The experiment also assessed the cross-protective efficacy of sera from the smallpox vaccinated population and preliminarily assessed the inhibitory effect of anti-smallpox virus drugs against MPXV. CPEs can be observed on Vero E6 cells at 24 hours and Vero cells at 48 hours. The virus particles could be observed by transmission electron microscope, showing typical orthopoxvirus morphology. In addition, F3L and ATI genes which from MPXV A39R, B2R, HA genes which from orthopoxvirus were confirmed by conventional PCR and Sanger sequencing. The next generation sequencing (NGS) suggests that the MPXV strain belongs to B.1 branch of the West African linage, and has a highly identity with the sequence of the 2022 ongoing outbreak. PRNT50 results showed that 26.7% of sera from individuals born before 1981 who had been immunized with smallpox were positive, but no MPXV-neutralizing antibodies were found in sera from individuals born later. All four anti-smallpox virus drugs evaluated demonstrated inhibition of mpox virus.
Collapse
Affiliation(s)
- Yan Zeng
- Wuhan Institute of Biological Products Co., Ltd., Wuhan City, China
| | - Xiaoke Liu
- Wuhan Institute of Biological Products Co., Ltd., Wuhan City, China
| | - Yuwei Li
- Wuhan Institute of Biological Products Co., Ltd., Wuhan City, China
| | - Jia Lu
- Wuhan Institute of Biological Products Co., Ltd., Wuhan City, China
| | - Qin Wu
- Wuhan Institute of Biological Products Co., Ltd., Wuhan City, China
| | - Demiao Dan
- Wuhan Institute of Biological Products Co., Ltd., Wuhan City, China
| | - Shiyun Lv
- Wuhan Institute of Biological Products Co., Ltd., Wuhan City, China
| | - Fei Xia
- Wuhan Institute of Biological Products Co., Ltd., Wuhan City, China
| | - Chunxia Hu
- Wuhan Institute of Biological Products Co., Ltd., Wuhan City, China
| | - Jiali Li
- Wuhan Institute of Biological Products Co., Ltd., Wuhan City, China
| | - Hao Zhang
- Wuhan Institute of Biological Products Co., Ltd., Wuhan City, China
| | - Hongqiao Du
- Wuhan Institute of Biological Products Co., Ltd., Wuhan City, China
| | - Rui Jia
- China National Biotec Group (CNBG), Beijing City, China
| | - Kai Duan
- Wuhan Institute of Biological Products Co., Ltd., Wuhan City, China
| | - Zejun Wang
- Wuhan Institute of Biological Products Co., Ltd., Wuhan City, China
| | - Xinguo Li
- Wuhan Institute of Biological Products Co., Ltd., Wuhan City, China
| | - Xiaoming Yang
- China National Biotec Group (CNBG), Beijing City, China
| |
Collapse
|
20
|
Yang B, Zhu D, Zhou Y, Gong B, Hu Y, Zhang J, Huang S, Nian X, Li X, Li X, Duan K, Yang X. Liposome and QS-21 Combined Adjuvant Induces theHumoral and Cellular Responses of Acellular Pertussis Vaccine in a Mice Model. Vaccines (Basel) 2023; 11:vaccines11050914. [PMID: 37243018 DOI: 10.3390/vaccines11050914] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Revised: 04/21/2023] [Accepted: 04/25/2023] [Indexed: 05/28/2023] Open
Abstract
The resurgence of pertussis in vaccinated communities may be related to the reduced long-term immunity induced by acellular pertussis vaccines. Therefore, developing improved pertussis vaccine candidates that could induce strong Th1 or Th17 cellular immunity is an urgent need. The use of new adjuvants may well meet this requirement. In this research, we developed a novel adjuvant candidate by combining liposome and QS-21 adjuvant. Adjuvant activity, protective efficacy, the level of neutralizing antibody against PT, and the resident memory T (TRM) cells in lung tissue after vaccination were studied. We then performed B. pertussis respiratory challenge in mice after they received vaccination with traditional aluminum hydroxide and the novel adjuvant combination. Results showed that the liposome + QS-21 adjuvant group had a rapid antibody and higher antibody (PT, FHA, Fim) level, induced anti-PT neutralizing antibody and recruited more IL-17A-secreting CD4+ TRM cells along with IL-17A-secreting CD8+ TRM cells in mice, which provided robust protection against B. pertussis infection. These results provide a key basis for liposome + QS-21 adjuvant as a promising adjuvant candidate for developing an acellular pertussis vaccine that elicits protective immunity against pertussis.
Collapse
Affiliation(s)
- Baifeng Yang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Dewu Zhu
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Yisi Zhou
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Beizhe Gong
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Yuan Hu
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Jiayou Zhang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Shihe Huang
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Xuanxuan Nian
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Xinghang Li
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Xinguo Li
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Kai Duan
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Xiaoming Yang
- National Biotec Group Company Limited, Beijing 100024, China
| |
Collapse
|
21
|
Nian X, Liu H, Cai M, Duan K, Yang X. Coping Strategies for Pertussis Resurgence. Vaccines (Basel) 2023; 11:889. [PMID: 37242993 PMCID: PMC10220650 DOI: 10.3390/vaccines11050889] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Revised: 04/20/2023] [Accepted: 04/21/2023] [Indexed: 05/28/2023] Open
Abstract
Pertussis (whooping cough) is a respiratory disease caused primarily by Bordetella pertussis, a Gram-negative bacteria. Pertussis is a relatively contagious infectious disease in people of all ages, mainly affecting newborns and infants under 2 months of age. Pertussis is undergoing a resurgence despite decades of high rates of vaccination. To better cope with the challenge of pertussis resurgence, we evaluated its possible causes and potential countermeasures in the narrative review. Expanded vaccination coverage, optimized vaccination strategies, and the development of a new pertussis vaccine may contribute to the control of pertussis.
Collapse
Affiliation(s)
- Xuanxuan Nian
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Hongbo Liu
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Mengyao Cai
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Kai Duan
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Xiaoming Yang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
- China National Biotech Group Company Limited, Bejing 100029, China
| |
Collapse
|
22
|
Duan K, Zhou M, Wang Y, Oberholzer J, Lo JF. Visualizing hypoxic modulation of beta cell secretions via a sensor augmented oxygen gradient. Microsyst Nanoeng 2023; 9:14. [PMID: 36760229 PMCID: PMC9902275 DOI: 10.1038/s41378-022-00482-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Revised: 11/04/2022] [Accepted: 11/27/2022] [Indexed: 06/18/2023]
Abstract
One distinct advantage of microfluidic-based cell assays is their scalability for multiple concentrations or gradients. Microfluidic scaling can be extremely powerful when combining multiple parameters and modalities. Moreover, in situ stimulation and detection eliminates variability between individual bioassays. However, conventional microfluidics must combat diffusion, which limits the spatial distance and time for molecules traveling through microchannels. Here, we leveraged a multilayered microfluidic approach to integrate a novel oxygen gradient (0-20%) with an enhanced hydrogel sensor to study pancreatic beta cells. This enabled our microfluidics to achieve spatiotemporal detection that is difficult to achieve with traditional microfluidics. Using this device, we demonstrated the in situ detection of calcium, insulin, and ATP (adenosine triphosphate) in response to glucose and oxygen stimulation. Specifically, insulin was quantified at levels as low as 25 pg/mL using our imaging technique. Furthermore, by analyzing the spatial detection data dynamically over time, we uncovered a new relationship between oxygen and beta cell oscillations. We observed an optimum oxygen level between 10 and 12%, which is neither hypoxic nor normoxic in the conventional cell culture sense. These results provide evidence to support the current islet oscillator model. In future applications, this spatial microfluidic technique can be adapted for discrete protein detection in a robust platform to study numerous oxygen-dependent tissue dysfunctions.
Collapse
Affiliation(s)
- Kai Duan
- Department of Mechanical Engineering, Bioengineering Program, University of Michigan at Dearborn, Dearborn, MI 48128 USA
| | - Mengyang Zhou
- Department of Mechanical Engineering, Bioengineering Program, University of Michigan at Dearborn, Dearborn, MI 48128 USA
| | - Yong Wang
- Department of Surgery/Transplant, University of Virginia, Charlottesville, VA 22908 USA
| | - Jose Oberholzer
- Department of Surgery/Transplant, University of Virginia, Charlottesville, VA 22908 USA
| | - Joe F. Lo
- Department of Mechanical Engineering, Bioengineering Program, University of Michigan at Dearborn, Dearborn, MI 48128 USA
| |
Collapse
|
23
|
Duan K, Orabi M, Warchock A, Al-Akraa Z, Ajami Z, Chun TH, Lo JF. Monolithically 3D-Printed Microfluidics with Embedded µTesla Pump. Micromachines (Basel) 2023; 14:mi14020237. [PMID: 36837937 PMCID: PMC9965163 DOI: 10.3390/mi14020237] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/03/2022] [Revised: 01/10/2023] [Accepted: 01/11/2023] [Indexed: 06/08/2023]
Abstract
Microfluidics has earned a reputation for providing numerous transformative but disconnected devices and techniques. Active research seeks to address this challenge by integrating microfluidic components, including embedded miniature pumps. However, a significant portion of existing microfluidic integration relies on the time-consuming manual fabrication that introduces device variations. We put forward a framework for solving this disconnect by combining new pumping mechanics and 3D printing to demonstrate several novel, integrated and wirelessly driven microfluidics. First, we characterized the simplicity and performance of printed microfluidics with a minimum feature size of 100 µm. Next, we integrated a microtesla (µTesla) pump to provide non-pulsatile flow with reduced shear stress on beta cells cultured on-chip. Lastly, the integration of radio frequency (RF) device and a hobby-grade brushless motor completed a self-enclosed platform that can be remotely controlled without wires. Our study shows how new physics and 3D printing approaches not only provide better integration but also enable novel cell-based studies to advance microfluidic research.
Collapse
Affiliation(s)
- Kai Duan
- Department of Mechanical Engineering, University of Michigan–Dearborn, Dearborn, MI 48128, USA
| | - Mohamad Orabi
- Department of Mechanical Engineering, University of Michigan–Dearborn, Dearborn, MI 48128, USA
| | - Alexus Warchock
- Department of Mechanical Engineering, University of Michigan–Dearborn, Dearborn, MI 48128, USA
| | - Zaynab Al-Akraa
- Department of Mechanical Engineering, University of Michigan–Dearborn, Dearborn, MI 48128, USA
| | - Zeinab Ajami
- Department of Mechanical Engineering, University of Michigan–Dearborn, Dearborn, MI 48128, USA
| | - Tae-Hwa Chun
- Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA
| | - Joe F. Lo
- Department of Mechanical Engineering, University of Michigan–Dearborn, Dearborn, MI 48128, USA
| |
Collapse
|
24
|
Liang H, Nian X, Wu J, Liu D, Feng L, Lu J, Peng Y, Zhou Z, Deng T, Liu J, Ji D, Qiu R, Lin L, Zeng Y, Xia F, Hu Y, Li T, Duan K, Li X, Wang Z, Zhang Y, Zhang H, Zhu C, Wang S, Wu X, Wang X, Li Y, Huang S, Mao M, Guo H, Yang Y, Jia R, Xufang J, Wang X, Liang S, Qiu Z, Zhang J, Ding Y, Li C, Zhang J, Fu D, He Y, Zhou D, Li C, Zhang J, Yu D, Yang XM. COVID-19 vaccination boosts the potency and breadth of the immune response against SARS-CoV-2 among recovered patients in Wuhan. Cell Discov 2022; 8:131. [PMID: 36494338 PMCID: PMC9734167 DOI: 10.1038/s41421-022-00496-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2022] [Accepted: 11/11/2022] [Indexed: 12/13/2022] Open
Abstract
The immunity of patients who recover from coronavirus disease 2019 (COVID-19) could be long lasting but persist at a lower level. Thus, recovered patients still need to be vaccinated to prevent reinfection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or its mutated variants. Here, we report that the inactivated COVID-19 vaccine can stimulate immunity in recovered patients to maintain high levels of anti-receptor-binding domain (RBD) and anti-nucleocapsid protein (NP) antibody titers within 9 months, and high neutralizing activity against the prototype, Delta, and Omicron strains was observed. Nevertheless, the antibody response decreased over time, and the Omicron variant exhibited more pronounced resistance to neutralization than the prototype and Delta strains. Moreover, the intensity of the SARS-CoV-2-specific CD4+ T cell response was also increased in recovered patients who received COVID-19 vaccines. Overall, the repeated antigen exposure provided by inactivated COVID-19 vaccination greatly boosted both the potency and breadth of the humoral and cellular immune responses against SARS-CoV-2, effectively protecting recovered individuals from reinfection by circulating SARS-CoV-2 and its variants.
Collapse
Affiliation(s)
- Hong Liang
- Beijing Tiantan Biological Products Co., Ltd., Beijing, China
| | - Xuanxuan Nian
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, Hubei China ,grid.433798.20000 0004 0619 8601Wuhan Institute of Biological Products Co., Ltd., Wuhan, Hubei China
| | - Junzheng Wu
- Chengdu Rongsheng Pharmaceuticals Co., Ltd., Chengdu, Sichuan China
| | - Dong Liu
- Beijing Tiantan Biological Products Co., Ltd., Beijing, China
| | - Lu Feng
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd., Wuhan, Hubei China
| | - Jia Lu
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, Hubei China ,grid.433798.20000 0004 0619 8601Wuhan Institute of Biological Products Co., Ltd., Wuhan, Hubei China
| | - Yan Peng
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd., Wuhan, Hubei China
| | - Zhijun Zhou
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd., Wuhan, Hubei China
| | - Tao Deng
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, Hubei China ,grid.433798.20000 0004 0619 8601Wuhan Institute of Biological Products Co., Ltd., Wuhan, Hubei China
| | - Jing Liu
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, Hubei China ,grid.433798.20000 0004 0619 8601Wuhan Institute of Biological Products Co., Ltd., Wuhan, Hubei China
| | - Deming Ji
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd., Wuhan, Hubei China
| | - Ran Qiu
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, Hubei China ,grid.433798.20000 0004 0619 8601Wuhan Institute of Biological Products Co., Ltd., Wuhan, Hubei China
| | - Lianzhen Lin
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd., Wuhan, Hubei China
| | - Yan Zeng
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, Hubei China ,grid.433798.20000 0004 0619 8601Wuhan Institute of Biological Products Co., Ltd., Wuhan, Hubei China
| | - Fei Xia
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, Hubei China ,grid.433798.20000 0004 0619 8601Wuhan Institute of Biological Products Co., Ltd., Wuhan, Hubei China
| | - Yong Hu
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd., Wuhan, Hubei China
| | - Taojing Li
- Beijing Tiantan Biological Products Co., Ltd., Beijing, China
| | - Kai Duan
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, Hubei China ,grid.433798.20000 0004 0619 8601Wuhan Institute of Biological Products Co., Ltd., Wuhan, Hubei China
| | - Xinguo Li
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, Hubei China ,grid.433798.20000 0004 0619 8601Wuhan Institute of Biological Products Co., Ltd., Wuhan, Hubei China
| | - Zejun Wang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, Hubei China ,grid.433798.20000 0004 0619 8601Wuhan Institute of Biological Products Co., Ltd., Wuhan, Hubei China
| | - Yong Zhang
- Beijing Tiantan Biological Products Co., Ltd., Beijing, China
| | - Hang Zhang
- Beijing Tiantan Biological Products Co., Ltd., Beijing, China
| | - Chen Zhu
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd., Wuhan, Hubei China
| | - Shang Wang
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd., Wuhan, Hubei China
| | - Xiao Wu
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd., Wuhan, Hubei China
| | - Xiang Wang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, Hubei China ,grid.433798.20000 0004 0619 8601Wuhan Institute of Biological Products Co., Ltd., Wuhan, Hubei China
| | - Yuwei Li
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, Hubei China ,grid.433798.20000 0004 0619 8601Wuhan Institute of Biological Products Co., Ltd., Wuhan, Hubei China
| | - Shihe Huang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, Hubei China ,grid.433798.20000 0004 0619 8601Wuhan Institute of Biological Products Co., Ltd., Wuhan, Hubei China
| | - Min Mao
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd., Wuhan, Hubei China
| | - Huanhuan Guo
- Wuxue Wusheng Plasma Collection Center, Wuxue, Hubei China
| | - Yunkai Yang
- China National Biotec Group Company Limited, Beijing, China
| | - Rui Jia
- China National Biotec Group Company Limited, Beijing, China
| | - Jingwei Xufang
- China National Biotec Group Company Limited, Beijing, China
| | - Xuewei Wang
- China National Biotec Group Company Limited, Beijing, China
| | | | - Zhixin Qiu
- Wuhan Biobank Co., Ltd., Wuhan, Hubei China
| | - Juan Zhang
- Wuhan Biobank Co., Ltd., Wuhan, Hubei China
| | - Yaling Ding
- Chengdu Rongsheng Pharmaceuticals Co., Ltd., Chengdu, Sichuan China
| | - Chunyan Li
- Beijing Tiantan Biological Products Co., Ltd., Beijing, China
| | - Jin Zhang
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd., Wuhan, Hubei China
| | - Daoxing Fu
- Beijing Tiantan Biological Products Co., Ltd., Beijing, China
| | - Yanlin He
- Beijing Tiantan Biological Products Co., Ltd., Beijing, China ,Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd., Wuhan, Hubei China
| | - Dongbo Zhou
- Beijing Tiantan Biological Products Co., Ltd., Beijing, China
| | - Cesheng Li
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd., Wuhan, Hubei China
| | - Jiayou Zhang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, Hubei China ,grid.433798.20000 0004 0619 8601Wuhan Institute of Biological Products Co., Ltd., Wuhan, Hubei China
| | - Ding Yu
- Beijing Tiantan Biological Products Co., Ltd., Beijing, China ,Chengdu Rongsheng Pharmaceuticals Co., Ltd., Chengdu, Sichuan China
| | - Xiao-Ming Yang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan, Hubei China ,China National Biotec Group Company Limited, Beijing, China
| |
Collapse
|
25
|
Chen J, Jin P, Chen X, Mao Q, Meng F, Li X, Chen W, Du M, Gao F, Liu P, Li X, Guo C, Xie T, Lu W, Li Q, Li L, Yan X, Guo X, Du H, Li X, Duan K, Zhu F. Clinical evaluation of the lot-to-lot consistency of an enterovirus 71 vaccine in a commercial-scale phase IV clinical trial. Hum Vaccin Immunother 2022; 18:2063630. [PMID: 35714273 PMCID: PMC9897631 DOI: 10.1080/21645515.2022.2063630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
OBJECTIVE To evaluate the immunogenicity, safety and lot-to-lot consistency of an inactivated enterovirus 71 (EV71) vaccine cultured in bioreactors with different specifications after full immunization. METHODS A randomized, double-blind trial was performed in 3,000 children aged 6 ~ 35 months with six vaccine batches, which were prepared in 40 L and 150 L bioreactors for three consecutive batches respectively. Children were immunized on day 0 and 28, serum samples were collected on day 0 and 56, and neutralizing antibody titers were determined by the microcytopathic method. Immediate reactions were recorded within 30 min, local and systemic symptoms were recorded within 0 ~ 28 days, and serious adverse events were recorded within 6 months. RESULTS After immunization with two doses of the inactivated EV71 vaccine, the neutralizing antibody GMT was 825.52 ± 4.09, and the positive conversion rate was 96.18%, with no significant difference. The 95% CI of the serum neutralizing antibody GMT ratio between the two groups after immunization with the three vaccine batches produced in the 150 L and 40 L bioreactors ranged from .67 ~ 1.5. The overall incidence of adverse reactions, mainly grade 1 reactions, for all 6 batches from 0 to 28 days after vaccination was 49.62%, with no significant difference (p = .8736). The incidence of systemic adverse reactions, primarily fever and diarrhea, was 45.14%; the incidence of local adverse reactions, primarily erythema and tenderness, was 9.43%. CONCLUSION The EV71 vaccine was highly immunogenic and safe in children aged 6-35 months, and 6 consecutive batches produced by the two bioreactors with different specifications were consistent.
Collapse
Affiliation(s)
- Jinhua Chen
- Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China
| | - Pengfei Jin
- Department of Vaccine Clinical Evaluation, Jiangsu Provincial Center of Disease Control and Prevention, Nanjing, Jiangsu, China
| | - Xiaoqi Chen
- Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China
| | - Qunying Mao
- Division of Hepatitis virus and Enterovirus Vaccine, National Institutes for Food and Drug Control, Beijing, China
| | - Fanyue Meng
- Department of Vaccine Clinical Evaluation, Jiangsu Provincial Center of Disease Control and Prevention, Nanjing, Jiangsu, China
| | - Xinguo Li
- Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China
| | - Wei Chen
- Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China
| | - Meizhi Du
- Department of Disease Prevention and Control, Pei County Center for Disease Control and Prevention, Pei County, Jiangsu, China
| | - Fan Gao
- Division of Hepatitis virus and Enterovirus Vaccine, National Institutes for Food and Drug Control, Beijing, China
| | - Pei Liu
- School of Public Health, Southeast University, Nanjing, Jiangsu, China
| | - Xiujuan Li
- Department of Disease Prevention and Control, Pei County Center for Disease Control and Prevention, Pei County, Jiangsu, China
| | - Changfu Guo
- Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China
| | - Tingbo Xie
- Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China
| | - Weiwei Lu
- Department of Research and Development, National Vaccine & Serum Institute, Beijing, China
| | - Qingliang Li
- Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China
| | - Li Li
- Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China
| | - Xing Yan
- Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China
| | - Xiang Guo
- Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China
| | - Hongqiao Du
- Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China
| | - Xiuling Li
- Department of Research and Development, Shanghai Institute of Biological Products Co., Ltd, Shanghai, China,CONTACT Fengcai Zhu No.172, Jiangsu Road, Nanjing City, Jiangsu Province, 210009, China
| | - Kai Duan
- Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China,Xiuling Li No. 758, Guangfeng Road, Fengxian District, Shanghai, 200050, China
| | - Fengcai Zhu
- Department of Vaccine Clinical Evaluation, Jiangsu Provincial Center of Disease Control and Prevention, Nanjing, Jiangsu, China,Kai Duan No. 1, Huangjin Industrial Park Road, Zhengdian, Jiangxia District, Wuhan, Hubei, 430207, China
| |
Collapse
|
26
|
Yu H, Zhang C, Cai Y, Wu N, Duan K, Bo W, Liu Y, Xu Z. Abnormal regional homogeneity and amplitude of low frequency fluctuation in chronic kidney patients with and without dialysis. Front Neurosci 2022; 16. [PMID: 36483180 PMCID: PMC9723135 DOI: 10.3389/fnins.2022.1064813] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2023] Open
Abstract
PurposeThe study characterizes regional homogeneity (ReHo) and amplitude of low frequency fluctuations (ALFF) in abnormal regions of brain in patients of chronic kidney disease (CKD).Materials and methodsA total of 64 patients of CKD were divided into 26 cases of non-dialysis-dependent chronic kidney disease (NDD-CKD), and 38 cases of dialysis-dependent chronic kidney disease (DD-CKD). A total of 43 healthy controls (normal control, NC) were also included. All subjects underwent resting-state functional magnetic resonance imaging (rs-fMRI). ALFF and ReHo data was processed for monitoring the differences in spontaneous brain activity between the three groups. ALFF and ReHo values of extracted differential brain regions were correlated to the clinical data and cognitive scores of CKD patients.ResultsNon-dialysis-dependent group has increased ALFF levels in 13 brain regions while that of DD group in 28 brain regions as compared with NC group. ReHo values are altered in six brain regions of DD group. ALFF is correlated with urea nitrogen and ReHo with urea nitrogen and creatinine. DD group has altered ReHo in two brain regions compared with NDD group. The differences are located in basal ganglia, cerebellar, and hippocampus regions.ConclusionAbnormal activity in basal ganglia, cerebellar, and hippocampal regions may be involved in the cognitive decline of CKD patients. This link can provide theoretical basis for understanding the cognitive decline.
Collapse
|
27
|
Zhang J, Nian X, Li X, Huang S, Duan K, Li X, Yang X. The Epidemiology of Influenza and the Associated Vaccines Development in China: A Review. Vaccines (Basel) 2022; 10:1873. [PMID: 36366381 PMCID: PMC9692979 DOI: 10.3390/vaccines10111873] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2022] [Revised: 10/28/2022] [Accepted: 11/03/2022] [Indexed: 12/28/2023] Open
Abstract
Influenza prevention and control has been one of the biggest challenges encountered in the public health domain. The vaccination against influenza plays a pivotal role in the prevention of influenza, particularly for the elderly and small children. According to the epidemiology of influenza in China, the nation is under a heavy burden of this disease. Therefore, as a contribution to the prevention and control of influenza in China through the provision of relevant information, the present report discusses the production and batch issuance of the influenza vaccine, analysis of the vaccination status and vaccination rate of the influenza vaccine, and the development trend of the influenza vaccine in China.
Collapse
Affiliation(s)
- Jiayou Zhang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Xuanxuan Nian
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Xuedan Li
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Shihe Huang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Kai Duan
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Xinguo Li
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Xiaoming Yang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
- China National Biotech Group Company Ltd., Beijing 100029, China
| |
Collapse
|
28
|
Tong Y, Zhang X, Chen J, Chen W, Wang Z, Li Q, Duan K, Wei S, Yang B, Qian X, Li J, Hang L, Deng S, Li X, Guo C, Shen H, Liu Y, Deng P, Xie T, Li Q, Li L, Du H, Mao Q, Gao F, Lu W, Guan X, Huang J, Li X, Chen X. Immunogenicity and safety of an enterovirus 71 vaccine in children aged 36-71 months: A double-blind, randomised, similar vaccine-controlled, non-inferiority phase III trial. EClinicalMedicine 2022; 52:101596. [PMID: 35923425 PMCID: PMC9340505 DOI: 10.1016/j.eclinm.2022.101596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/21/2022] [Revised: 07/08/2022] [Accepted: 07/13/2022] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND The enterovirus 71 (EV71) vaccine produced by Wuhan Institute of Biological Products Co., Ltd. (WIBP) (B-EV71) has been given to children aged 6-35 months, and it has shown good safety, immunogenicity and efficacy. However, the administration of EV71 vaccine in children aged 36-71 months, which is another target population, needs further exploration. METHODS We conducted a double-blind, randomised, controlled, non-inferiority phase III clinical trial in children aged 36-71 months, with a further comparison group of children aged 6-35 months in China. Children aged 6-71 months with no history of hand, foot and mouth disease or prior-vaccination of EV71 vaccine were eligible and recruited. Eligible participants aged 36-71 months were randomly assigned (1:1) to receive two doses of the B-EV71 vaccine (Older-B group) or the control EV71 vaccine (C-EV71 vaccine, produced by Institute of Medical Biology, Chinese Academy of Medical Sciences) (Older-C group), administered at a 30-day interval. Eligible participants aged 6-35 months were enrolled consecutively to receive two doses of the B-EV71 vaccine (Younger-B group) at a 30-day interval. Participants, investigators and those assessing outcomes were masked to the vaccine received. Non-inferiority analyses were conducted to compare the immunogenicity of EV71 vaccine in the Older-B group with that in the Older-C and Younger-B groups. Non-inferiority margins were 10% for seroconversion rate differences and 0.5 for geometric mean titre (GMT) ratios. The primary endpoints were the GMT level and seroconversion rate of anti-EV71 neutralising antibody 30 days after the second dose of vaccination. The primary analysis was performed in the per-protocol population. Safety analyses were conducted amongst participants receiving at least one dose of vaccine. This trial was registered at Chinadrugtrials.org.cn (#CTR20192345). FINDINGS Between June 3 and June 30, 2020, 1600 participants were enrolled and assigned, including 625 participants in the Older-B group, 625 participants in the Older-C group and 350 participants in the Younger-B group. The seroconversion rate of anti-EV71 neutralising antibody in the Older-B group (99.66%; 95% CI: 99.18%-100.00%) was non-inferior to that of the Older-C (99.32%; 95% CI: 98.65%-99.98%) and Younger-B groups (100.00%; 95% CI: 100.00%-100.00%). The differences in seroconversion rates in the Older-B group to those in the Older-C and Younger-B groups were 0.34% (95%CI: -2.17%-2.86%) and -0.34% (95%CI: -2.78%-2.09%). The GMT of the anti-EV71 neutralising antibody in the Older-B group (693.87) was also non-inferior to that in the Older-C (289.37) and Younger-B groups (634.80). The ratios of GMTs in the Older-B group to those in the Older-C and Younger-B groups were 2.67 (95%CI: 2.00-3.00) and 1.00 (95%CI: 0.75-1.00), respectively. The incidence of any adverse event (AE) related to vaccination was similar amongst the three groups (34/625 [5.44%] in the Older-B group, 32/623 [5.14%] in the Older-C group, and 26/349 [7.45%] in the Younger-B group), with only 2 (0.57%) participants having grade 3 AEs in the Younger-B group. Fifteen (0.94%) participants from these three groups had reported serious AEs (SAEs), all of which were unrelated to vaccines. INTERPRETATION EV71 vaccine produced by WIBP could extend to be administered to children aged 36-71 months against EV71 infection. However, the persistence of vaccine-induced immunities needs to be further investigated. FUNDING Hubei Province's young medical talent program (20191229), Hubei Province's young talent program (2021), Hubei Province's young public health talent program (2021); and the Wuhan Institute of Biological Products Co., Ltd.
Collapse
Affiliation(s)
- Yeqing Tong
- Hubei Provincial Centre for Disease Control and Prevention, Wuhan, China
| | - Xinyue Zhang
- Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Jinhua Chen
- Wuhan Institute of Biological Products Co., Ltd, Wuhan, China
| | - Wei Chen
- Wuhan Institute of Biological Products Co., Ltd, Wuhan, China
| | - Zhao Wang
- Hubei Provincial Centre for Disease Control and Prevention, Wuhan, China
| | - Qiong Li
- Hubei Provincial Centre for Disease Control and Prevention, Wuhan, China
| | - Kai Duan
- Wuhan Institute of Biological Products Co., Ltd, Wuhan, China
| | - Sheng Wei
- Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Beifang Yang
- Hubei Provincial Centre for Disease Control and Prevention, Wuhan, China
| | - Xiaoai Qian
- Hubei Provincial Centre for Disease Control and Prevention, Wuhan, China
| | - Jiahong Li
- Xiangzhou District Centre for Disease Control and Prevention, Wuhan, China
| | - Lianju Hang
- Xiangzhou District Centre for Disease Control and Prevention, Wuhan, China
| | - Shaoyong Deng
- Xiangzhou District Centre for Disease Control and Prevention, Wuhan, China
| | - Xinguo Li
- Wuhan Institute of Biological Products Co., Ltd, Wuhan, China
| | - Changfu Guo
- Wuhan Institute of Biological Products Co., Ltd, Wuhan, China
| | - Heng Shen
- Hubei Provincial Centre for Disease Control and Prevention, Wuhan, China
| | - Yan Liu
- Hubei Provincial Centre for Disease Control and Prevention, Wuhan, China
| | - Peng Deng
- Hubei Provincial Centre for Disease Control and Prevention, Wuhan, China
| | - Tingbo Xie
- Wuhan Institute of Biological Products Co., Ltd, Wuhan, China
| | - Qingliang Li
- Wuhan Institute of Biological Products Co., Ltd, Wuhan, China
| | - Li Li
- Wuhan Institute of Biological Products Co., Ltd, Wuhan, China
| | - Hongqiao Du
- Wuhan Institute of Biological Products Co., Ltd, Wuhan, China
| | - Qunying Mao
- National Institutes for Food and Drug Control, Beijing, China
| | - Fan Gao
- National Institutes for Food and Drug Control, Beijing, China
| | - Weiwei Lu
- National Vaccine &Serum Institute, Beijing, China
| | - Xuhua Guan
- Hubei Provincial Centre for Disease Control and Prevention, Wuhan, China
- Corresponding authors.
| | - Jiao Huang
- Centre for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China
- Corresponding authors.
| | - Xiuling Li
- Shanghai Institute of Biological Products Co., Ltd, Shanghai, China
- Corresponding authors.
| | - Xiaoqi Chen
- Wuhan Institute of Biological Products Co., Ltd, Wuhan, China
- Corresponding authors.
| |
Collapse
|
29
|
Nian X, Zhang J, Huang S, Duan K, Li X, Yang X. Development of Nasal Vaccines and the Associated Challenges. Pharmaceutics 2022; 14:1983. [PMID: 36297419 PMCID: PMC9609876 DOI: 10.3390/pharmaceutics14101983] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2022] [Revised: 09/16/2022] [Accepted: 09/16/2022] [Indexed: 02/02/2024] Open
Abstract
Viruses, bacteria, fungi, and several other pathogenic microorganisms usually infect the host via the surface cells of respiratory mucosa. Nasal vaccination could provide a strong mucosal and systemic immunity to combat these infections. The intranasal route of vaccination offers the advantage of easy accessibility over the injection administration. Therefore, nasal immunization is considered a promising strategy for disease prevention, particularly in the case of infectious diseases of the respiratory system. The development of a nasal vaccine, particularly the strategies of adjuvant and antigens design and optimization, enabling rapid induction of protective mucosal and systemic responses against the disease. In recent times, the development of efficacious nasal vaccines with an adequate safety profile has progressed rapidly, with effective handling and overcoming of the challenges encountered during the process. In this context, the present report summarizes the most recent findings regarding the strategies used for developing nasal vaccines as an efficient alternative to conventional vaccines.
Collapse
Affiliation(s)
- Xuanxuan Nian
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Jiayou Zhang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Shihe Huang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Kai Duan
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Xinguo Li
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
| | - Xiaoming Yang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China
- China National Biotech Group Company Limited, Beijing 100029, China
| |
Collapse
|
30
|
Li X, Pan Y, Yin Q, Wang Z, Shan S, Zhang L, Yu J, Qu Y, Sun L, Gui F, Lu J, Jing Z, Wu W, Huang T, Shi X, Li J, Li X, Li D, Wang S, Yang M, Zhang L, Duan K, Liang M, Yang X, Wang X. Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages. Cell Discov 2022; 8:87. [PMID: 36075908 PMCID: PMC9453709 DOI: 10.1038/s41421-022-00449-4] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2022] [Accepted: 07/23/2022] [Indexed: 11/19/2022] Open
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs), especially the latest Omicron, have exhibited severe antibody evasion. Broadly neutralizing antibodies with high potency against Omicron are urgently needed for understanding the working mechanisms and developing therapeutic agents. In this study, we characterized the previously reported F61, which was isolated from convalescent patients infected with prototype SARS-CoV-2, as a broadly neutralizing antibody against all VOCs including Omicron BA.1, BA.1.1, BA.2, BA.3 and BA.4 sublineages by utilizing antigen binding and cell infection assays. We also identified and characterized another broadly neutralizing antibody D2 with epitope distinct from that of F61. More importantly, we showed that a combination of F61 with D2 exhibited synergy in neutralization and protecting mice from SARS-CoV-2 Delta and Omicron BA.1 variants. Cryo-Electron Microscopy (Cryo-EM) structures of the spike-F61 and spike-D2 binary complexes revealed the distinct epitopes of F61 and D2 at atomic level and the structural basis for neutralization. Cryo-EM structure of the Omicron-spike-F61-D2 ternary complex provides further structural insights into the synergy between F61 and D2. These results collectively indicated F61 and F61-D2 cocktail as promising therapeutic antibodies for combating SARS-CoV-2 variants including diverse Omicron sublineages.
Collapse
Affiliation(s)
- Xiaoman Li
- The Ministry of Education Key Laboratory of Protein Science, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, School of Life Sciences, Tsinghua University, Beijing, China
| | - Yongbing Pan
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Qiangling Yin
- State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zejun Wang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Sisi Shan
- NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China
| | - Laixing Zhang
- The Ministry of Education Key Laboratory of Protein Science, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, School of Life Sciences, Tsinghua University, Beijing, China
| | - Jinfang Yu
- The Ministry of Education Key Laboratory of Protein Science, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, School of Life Sciences, Tsinghua University, Beijing, China
| | - Yuanyuan Qu
- Institution of Infectious Diseases, Shenzhen Bay Laboratory, Shenzhen, Guangdong, China
| | - Lina Sun
- State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Fang Gui
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Jia Lu
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Zhaofei Jing
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Wei Wu
- State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Tao Huang
- State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Xuanling Shi
- NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China
| | - Jiandong Li
- State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Xinguo Li
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Dexin Li
- State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.,CDC-WIV Joint Research Center for Emerging Diseases and Biosafety, Wuhan, Hubei, China
| | - Shiwen Wang
- State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.,CDC-WIV Joint Research Center for Emerging Diseases and Biosafety, Wuhan, Hubei, China
| | - Maojun Yang
- The Ministry of Education Key Laboratory of Protein Science, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, School of Life Sciences, Tsinghua University, Beijing, China
| | - Linqi Zhang
- NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China
| | - Kai Duan
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Mifang Liang
- State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China. .,CDC-WIV Joint Research Center for Emerging Diseases and Biosafety, Wuhan, Hubei, China.
| | - Xiaoming Yang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China.
| | - Xinquan Wang
- The Ministry of Education Key Laboratory of Protein Science, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, School of Life Sciences, Tsinghua University, Beijing, China.
| |
Collapse
|
31
|
Wu Z, Li Q, Liu Y, Lv H, Mo Z, Li F, Yu Q, Jin F, Chen W, Zhang Y, Huang T, Hu X, Xia W, Gao J, Zhou H, Bai X, Liu Y, Liang Z, Jiang Z, Chen Y, Zhang J, Du J, Yang B, Xing B, Xing Y, Dong B, Yang Q, Shi C, Yan T, Ruan B, Shi H, Fan X, Feng D, Lv W, Zhang D, Kong X, Zhou L, Que D, Chen H, Chen Z, Guo X, Zhou W, Wu C, Zhou Q, Liu Y, Qiao J, Wang Y, Li X, Duan K, Zhao Y, Yang X, Xu G. Efficacy, safety and immunogenicity of hexavalent rotavirus vaccine in Chinese infants. Virol Sin 2022; 37:724-730. [PMID: 35926726 PMCID: PMC9583109 DOI: 10.1016/j.virs.2022.07.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2022] [Accepted: 07/19/2022] [Indexed: 11/26/2022] Open
Abstract
A randomized, double-blind, placebo-controlled multicenter trial was conducted in healthy Chinese infants to assess the efficacy and safety of a hexavalent live human-bovine reassortant rotavirus vaccine (HRV) against rotavirus gastroenteritis (RVGE). A total of 6400 participants aged 6–12 weeks were enrolled and randomly assigned to either HRV (n = 3200) or placebo (n = 3200) group. All the subjects received three oral doses of vaccine four weeks apart. The vaccine efficacy (VE) against RVGE caused by rotavirus serotypes contained in HRV was evaluated from 14 days after three doses of administration up until the end of the second rotavirus season. VE against severe RVGE, VE against RVGE hospitalization caused by serotypes contained in HRV, and VE against RVGE, severe RVGE, and RVGE hospitalization caused by natural infection of any serotype of rotavirus were also investigated. All adverse events (AEs) were collected for 30 days after each dose. Serious AEs (SAEs) and intussusception cases were collected during the entire study. Our data showed that VE against RVGE caused by serotypes contained in HRV was 69.21% (95%CI: 53.31–79.69). VE against severe RVGE and RVGE hospitalization caused by serotypes contained in HRV were 91.36% (95%CI: 78.45–96.53) and 89.21% (95%CI: 64.51–96.72) respectively. VE against RVGE, severe RVGE, and RVGE hospitalization caused by natural infection of any serotype of rotavirus were 62.88% (95%CI: 49.11–72.92), 85.51% (95%CI: 72.74–92.30) and 83.68% (95%CI: 61.34–93.11). Incidences of AEs from the first dose to one month post the third dose in HRV and placebo groups were comparable. There was no significant difference in incidences of SAEs in HRV and placebo groups. This study shows that this hexavalent reassortant rotavirus vaccine is an effective, well-tolerated, and safe vaccine for Chinese infants. A multicenter, double-blind, phase III clinical trial for the efficacy and safety of hexavalent rotavirus vaccine (HRV). The vaccine efficacy against rotavirus gastroenteritis caused by serotypes contained in HRV was 69.21%. The efficacy against severe rotavirus gastroenteritis and hospitalization caused by serotypesin HRV were 91.36% and 89.21%. No significant difference between the incidences of adverse events and severe adverse events in HRV and placebo group. This hexavalent live human-bovine reassortant rotavirus vaccine iseffective, well tolerated and safe in Chinese infants.
Collapse
Affiliation(s)
- Zhiwei Wu
- Hebei Center for Disease Control and Prevention, Shijiazhuang, 050021, China
| | - Qingliang Li
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China
| | - Yan Liu
- National Institutes for Food and Drug Control, Beijing, 100050, China
| | - Huakun Lv
- Zhejiang Center for Disease Control and Prevention, Hangzhou, 310051, China
| | - Zhaojun Mo
- Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, 530028, China
| | - Fangjun Li
- Hunan Center for Disease Control and Prevention, Changsha, 410005, China
| | - Qingchuan Yu
- National Institutes for Food and Drug Control, Beijing, 100050, China
| | - Fei Jin
- Hebei Center for Disease Control and Prevention, Shijiazhuang, 050021, China
| | - Wei Chen
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China
| | - Yong Zhang
- National Institutes for Food and Drug Control, Beijing, 100050, China
| | - Teng Huang
- Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, 530028, China
| | - Xiaosong Hu
- Zhejiang Center for Disease Control and Prevention, Hangzhou, 310051, China
| | - Wei Xia
- Hunan Center for Disease Control and Prevention, Changsha, 410005, China
| | - Jiamei Gao
- National Institutes for Food and Drug Control, Beijing, 100050, China
| | - Haisong Zhou
- Zhengding County Center for Disease Control and Prevention, Shijiazhuang, 050800, China
| | - Xuan Bai
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China
| | - Yueyue Liu
- National Institutes for Food and Drug Control, Beijing, 100050, China
| | - Zhenzhen Liang
- Zhejiang Center for Disease Control and Prevention, Hangzhou, 310051, China
| | - Zhijun Jiang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China
| | - Yingping Chen
- Zhejiang Center for Disease Control and Prevention, Hangzhou, 310051, China
| | - Jiuwei Zhang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China
| | - Jialiang Du
- National Institutes for Food and Drug Control, Beijing, 100050, China
| | - Biao Yang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China
| | - Bo Xing
- Zhejiang Center for Disease Control and Prevention, Hangzhou, 310051, China
| | - Yantao Xing
- Daming County Center for Disease Control and Prevention, Handan, 056900, China
| | - Ben Dong
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China
| | - Qinghai Yang
- Liucheng County Center for Disease Control and Prevention, Liuzhou, 545200, China
| | - Chen Shi
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China
| | - Tingdong Yan
- Xiangtan County Center for Disease Control and Prevention, Xiangtan, 411228, China
| | - Bo Ruan
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China
| | - Haiyun Shi
- Yuhuan County Center for Disease Control and Prevention, Taizhou, 317600, China
| | - Xingliang Fan
- National Institutes for Food and Drug Control, Beijing, 100050, China
| | - Dongyang Feng
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China
| | - Weigang Lv
- Yongnian County Center for Disease Control and Prevention, Handan, 056000, China
| | - Dong Zhang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China
| | - Xiangchu Kong
- Rongshui Miao Autonomous County Center for Disease Control and Prevention, Liuzhou, 545300, China
| | - Liuyifan Zhou
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China
| | - Dinghong Que
- You County Center for Disease Control and Prevention, Zhuzhou, 412315, China
| | - Hong Chen
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China
| | - Zhongbing Chen
- Longyou County Center for Disease Control and Prevention, Quzhou, 324400, China
| | - Xiang Guo
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China
| | - Weiwei Zhou
- Laishui County Center for Disease Control and Prevention, Baoding 074100, China
| | - Cong Wu
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China
| | - Qingrong Zhou
- Jiangshan County Center for Disease Control and Prevention, Quzhou, 324100, China
| | - Yuqing Liu
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China
| | - Jian Qiao
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China
| | - Ying Wang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China
| | - Xinguo Li
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China
| | - Kai Duan
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China
| | - Yuliang Zhao
- Hebei Center for Disease Control and Prevention, Shijiazhuang, 050021, China.
| | - Xiaoming Yang
- China National Biotec Group Company Limited, National Engineering Technology Research Center for Combined Vaccines, Wuhan, 430207, China.
| | - Gelin Xu
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China.
| |
Collapse
|
32
|
Xia S, Duan K, Zhang Y, Zeng X, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang W, Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Li Q, Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S, Du J, Nian X, Deng T, Yuan Z, Shen S, Guo W, Liu J, Yang X. Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial. Front Immunol 2022; 13:898151. [PMID: 35812412 PMCID: PMC9265248 DOI: 10.3389/fimmu.2022.898151] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2022] [Accepted: 05/02/2022] [Indexed: 01/14/2023] Open
Abstract
Safe and effective vaccines against SARS-CoV-2 for children are urgently needed. Here we aimed to assess the safety and immunogenicity of an inactivated COVID-19 vaccine candidate, WIBP-CorV, in participants aged 3-17 years. A randomized, double-blind, placebo-controlled, phase 1/2 clinical trial was conducted in Henan Province, China, in healthy children aged 3-17 years. 240 participants in phase 1 trial and 576 participants in phase 2 trial were randomly assigned to vaccine or control with an age de-escalation in three cohorts (3-5, 6-12 and 13-17 years) and dose-escalation in three groups (2.5, 5.0 and 10.0μg/dose), and received 3 intramuscular injections at day 0, 28, and 56. WIBP-CorV showed a promising safety profile with approximately 17% adverse reactions within 30 days after injection and no grade 3 or worse adverse events. The most common adverse reaction was injection site pain, followed by fever, which were mild and self-limiting. The geometric mean titers of neutralizing antibody ranged from 102.2 to 1065.5 in vaccinated participants at 28 days after the third vaccination, and maintained at a range of 14.3 to 218.2 at day 180 after the third vaccination. WIBP-CorV elicited significantly higher titers of neutralizing antibody in the cohort aged 3-5 years than the other two cohorts. There were no detectable antibody responses in all alum-only groups. Taken together, our data demonstrate that WIBP-CorV is safe and well tolerated at all tested doses in participants aged 3-17 years, and elicited robust humoral responses against SARS-CoV-2 lasted for at least 6 months after the third vaccination. This study is ongoing and is registered with www.chictr.org.cn, ChiCTR2000031809.
Collapse
Affiliation(s)
- Shengli Xia
- Vaccine Clinical Research Center, Henan Center for Disease Control and Prevention, Zhengzhou, China
| | - Kai Duan
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China
| | - Yuntao Zhang
- Clinical Medical Center, China National Biotec Group Company Limited, Beijing, China
| | - Xiaoqing Zeng
- Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Dongyang Zhao
- Vaccine Clinical Research Center, Henan Center for Disease Control and Prevention, Zhengzhou, China
| | - Huajun Zhang
- Chinese Academy of Sciences Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China
| | - Zhiqiang Xie
- Vaccine Clinical Research Center, Henan Center for Disease Control and Prevention, Zhengzhou, China
| | - Xinguo Li
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China
| | - Cheng Peng
- Chinese Academy of Sciences Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China
| | - Wei Zhang
- Vaccine Clinical Research Center, Henan Center for Disease Control and Prevention, Zhengzhou, China
| | - Yunkai Yang
- Clinical Medical Center, China National Biotec Group Company Limited, Beijing, China
| | - Wei Chen
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China
| | - Xiaoxiao Gao
- Chinese Academy of Sciences Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China
| | - Wangyang You
- Vaccine Clinical Research Center, Henan Center for Disease Control and Prevention, Zhengzhou, China
| | - Xuewei Wang
- Clinical Medical Center, China National Biotec Group Company Limited, Beijing, China
| | - Zejun Wang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China
| | - Zhengli Shi
- Chinese Academy of Sciences Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China
| | - Yanxia Wang
- Vaccine Clinical Research Center, Henan Center for Disease Control and Prevention, Zhengzhou, China
| | - Xuqin Yang
- Clinical Medical Center, China National Biotec Group Company Limited, Beijing, China
| | - Qingliang Li
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China
| | - Lili Huang
- Vaccine Clinical Research Center, Henan Center for Disease Control and Prevention, Zhengzhou, China
| | - Qian Wang
- Clinical Medical Center, China National Biotec Group Company Limited, Beijing, China
| | - Jia Lu
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China
| | - Yongli Yang
- Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, China
| | - Jing Guo
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China
| | - Wei Zhou
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China
| | - Xin Wan
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China
| | - Cong Wu
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China
| | - Wenhui Wang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China
| | - Shihe Huang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China
| | - Jianhui Du
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China
| | - Xuanxuan Nian
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China
| | - Tao Deng
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China
| | - Zhiming Yuan
- Chinese Academy of Sciences Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China
| | - Shuo Shen
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China
| | - Wanshen Guo
- Vaccine Clinical Research Center, Henan Center for Disease Control and Prevention, Zhengzhou, China
| | - Jia Liu
- Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- *Correspondence: Xiaoming Yang, ; Jia Liu,
| | - Xiaoming Yang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China
- Clinical Medical Center, China National Biotec Group Company Limited, Beijing, China
- *Correspondence: Xiaoming Yang, ; Jia Liu,
| |
Collapse
|
33
|
Huang X, Fan T, Li L, Nian X, Zhang J, Gao X, Zhao W, Chen W, Zhang Z, Yao Z, Han X, Shi J, Wang Y, Bian H, Shi N, Li X, Duan K, Li G, Yang X. Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3-60 years: a phase III randomized clinical noninferiority trial. Hum Vaccin Immunother 2022; 18:2079924. [PMID: 35714276 PMCID: PMC9621009 DOI: 10.1080/21645515.2022.2079924] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Abstract
Background A quadrivalent split influenza vaccine IIV4-W against both influenza A and B viruses is urgently needed. Methods To evaluate the safety and immunogenicity of IIV4-W in people aged 3–60 years, 2400 participants recruited in a double-blind phase III trial and were randomly assigned to the IIV4-W, TIV1 and TIV2 groups. The immunogenicity indicators were measured at 28 days postvaccination and for 180 days for safety follow-up. Results Adverse events (AEs) occurred in 162 (20.28%), 116 (14.55%) and 123 (15.41%) participants in the IIV4-W, TIV1 and TIV2 groups, respectively. All these AEs were mild and self-limiting, and no serious AEs related to the vaccines were observed. IIV4-W elicited a non-inferior immune response for matched strains (the lower limit of 95% CI for GMT ratio >0.67, for SCR and SPR difference >-10%) and superior immune response for the additional B strains (the lower limit of 95% CI for GMT ratio >1.5, for SCR difference >10%) versus TIVs. The lower limit of the 95% confidence interval of the GMT increase fold, the seroconversion rate and the seroprotection rate exceeded 2.5, 40% and 70% for the four strains in IIV4-W respectively. Conclusions IIV4-W was noninferior to the TIV-matched strains and was superior to the additional B strain. IIV4-W was safe in the participants and elicited high antibody titers.
Collapse
Affiliation(s)
- Xiaoyuan Huang
- Wuhan Institute of Biological Products Co. Ltd, Wuhan, China
| | - Ting Fan
- Shanxi Provincial Centers for Disease Control and Prevention, Taiyuan, Shanxi, China
| | - Li Li
- Chaoyang Center for Disease Control and Prevention, Taiyuan, Shanxi, China
| | - Xuanxuan Nian
- Wuhan Institute of Biological Products Co. Ltd, Wuhan, China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, Hubei, China
| | - Jiayou Zhang
- Wuhan Institute of Biological Products Co. Ltd, Wuhan, China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, Hubei, China
| | - Xuefen Gao
- Shanxi Provincial Centers for Disease Control and Prevention, Taiyuan, Shanxi, China
| | - Wei Zhao
- Wuhan Institute of Biological Products Co. Ltd, Wuhan, China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, Hubei, China
| | - Wei Chen
- Wuhan Institute of Biological Products Co. Ltd, Wuhan, China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, Hubei, China
| | - Zhaoqing Zhang
- Qinyuan County Center for Disease Control and Prevention, Taiyuan, Shanxi, China
| | - Zhihao Yao
- Qinyuan County Center for Disease Control and Prevention, Taiyuan, Shanxi, China
| | - Xixin Han
- Wuhan Institute of Biological Products Co. Ltd, Wuhan, China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, Hubei, China
| | - Jinrong Shi
- Wuhan Institute of Biological Products Co. Ltd, Wuhan, China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, Hubei, China
| | - Ying Wang
- Wuhan Institute of Biological Products Co. Ltd, Wuhan, China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, Hubei, China
| | - Haihe Bian
- Quwo County Center for Disease Control and Prevention, Taiyuan, Shanxi, China
| | - Nianmin Shi
- Chaoyang Center for Disease Control and Prevention, Taiyuan, Shanxi, China
| | - Xinguo Li
- Wuhan Institute of Biological Products Co. Ltd, Wuhan, China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, Hubei, China
| | - Kai Duan
- Wuhan Institute of Biological Products Co. Ltd, Wuhan, China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, Hubei, China
| | - Guohua Li
- Shanxi Provincial Centers for Disease Control and Prevention, Taiyuan, Shanxi, China
| | - Xiaoming Yang
- National Engineering Technology Research Center of Combined Vaccines, Wuhan, Hubei, China.,China National Biotec Group Company Limited, Beijing, China
| |
Collapse
|
34
|
Wang XL, Duan K, Wei L. [Simulation of water and carbon coupling of the Pearl River basin based on the WaSSI model]. Ying Yong Sheng Tai Xue Bao 2022; 33:1377-1386. [PMID: 35730097 DOI: 10.13287/j.1001-9332.202205.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Watershed water and carbon cycles are closely linked through plant photosynthesis and evapotranspiration (ET). Simulation of coupled water-carbon cycles at the watershed scale is important for the comprehensive management of water and carbon resources. By improving the WaSSI (water supply stress index) eco-hydrological model, we established and verified a water-carbon coupling simulation model for the Pearl River Basin in south China (WaSSI-PRB). The Pearl River Basin was divided into 1715 watersheds. The simulations of three water-carbon flux parameters, such as runoff, ET and gross primary productivity (GPP), were verified with 1980-2004 as the calibration period and 2005-2016 as the validation period. The Nash-Sutcliffe efficiency coefficient (NSE) and the coefficient of determination (R2) of the simulated runoff at the controlling hydrological stations of Xijiang, Beijiang and Dongjiang were greater than 0.80 during calibration period and greater than 0.75 during validation period. Compared with MODIS, PML, SSEBop, VPM and other large-scale remote sensing data products, WASSI-PRB showed a better performance in capturing the spatiotemporal variations of ET and GPP. In general, WaSSI-PRB model had good applicability in the study area, and could be used as an effective tool to quantitatively analyze water-carbon balance and their responses to environmental changes in the Pearl River Basin.
Collapse
Affiliation(s)
- Xiao-la Wang
- School of Civil Engineering, Sun Yat-sen University, Guangzhou 510275, China
| | - Kai Duan
- School of Civil Engineering, Sun Yat-sen University, Guangzhou 510275, China
- Southern Marine Science and Engineering Guangdong Laboratory (Zhuhai), Zhuhai 519082, Guangdong, China
| | - Lin Wei
- School of Civil Engineering, Sun Yat-sen University, Guangzhou 510275, China
| |
Collapse
|
35
|
Lu J, Yin Q, Pei R, Zhang Q, Qu Y, Pan Y, Sun L, Gao D, Liang C, Yang J, Wu W, Li J, Cui Z, Wang Z, Li X, Li D, Wang S, Duan K, Guan W, Liang M, Yang X. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants. Virol Sin 2022; 37:238-247. [PMID: 35527227 PMCID: PMC8855614 DOI: 10.1016/j.virs.2022.02.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2022] [Accepted: 02/16/2022] [Indexed: 12/19/2022] Open
Abstract
Multiple new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have constantly emerged, as the delta and omicron variants, which have developed resistance to currently gained neutralizing antibodies. This highlights a critical need to discover new therapeutic agents to overcome the variants mutations. Despite the availability of vaccines against coronavirus disease 2019 (COVID-19), the use of broadly neutralizing antibodies has been considered as an alternative way for the prevention or treatment of SARS-CoV-2 variants infection. Here, we show that the nasal delivery of two previously characterized broadly neutralizing antibodies (F61 and H121) protected K18-hACE2 mice against lethal challenge with SARS-CoV-2 variants. The broadly protective efficacy of the F61 or F61/F121 cocktail antibodies was evaluated by lethal challenge with the wild strain (WIV04) and multiple variants, including beta (B.1.351), delta (B.1.617.2), and omicron (B.1.1.529) at 200 or 1000 TCID50, and the minimum antibody administration doses (5–1.25 mg/kg body weight) were also evaluated with delta and omicron challenge. Fully prophylactic protections were found in all challenged groups with both F61 and F61/H121 combination at the administration dose of 20 mg/kg body weight, and corresponding mice lung viral RNA showed negative, with almost all alveolar septa and cavities remaining normal. Furthermore, low-dose antibody treatment induced significant prophylactic protection against lethal challenge with delta and omicron variants, whereas the F61/H121 combination showed excellent results against omicron infection. Our findings indicated the potential use of broadly neutralizing monoclonal antibodies as prophylactic and therapeutic agent for protection of current emerged SARS-CoV-2 variants infection. The mAbs could be detected in lungs shortly after nasal spray and kept in the lungs for a long time. High dose mAbs nasal delivery could fully prophylactic protection mice from omicron lethal challenged. Significant enhancement of broadly neutralizing activity against variants were confirmed in F61 and H121 combination use.
Collapse
|
36
|
Yu H, Wang Z, Sun Y, Bo W, Duan K, Song C, Hu Y, Zhou J, Mu Z, Wu N. Prognosis of ischemic stroke predicted by machine learning based on multi-modal MRI radiomics. Front Psychiatry 2022; 13:1105496. [PMID: 36699499 PMCID: PMC9868394 DOI: 10.3389/fpsyt.2022.1105496] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/22/2022] [Accepted: 12/12/2022] [Indexed: 01/10/2023] Open
Abstract
OBJECTIVE Increased risk of stroke is highly associated with psychiatric disorders. We aimed to conduct the machine learning model based on multi-modal magnetic resonance imaging (MRI) radiomics predicting the prognosis of ischemic stroke. METHODS This study retrospectively analyzed 148 patients with acute ischemic stroke due to anterior circulation artery occlusion. Based on the modified Rankin Scale (mRS) score, patients were divided into good (mRS ≤ 2) and poor (mRS > 2) outcome groups. Segmentation of the infarct region was performed by manually outlining a mask of the lesion on diffusion-weighted images (DWI) using MRIcron software. The apparent diffusion coefficient (ADC), fluid decay inversion recoverage (FLAIR), susceptibility weighted imaging (SWI) and T1-weighted (T1w) images were aligned to the DWI images and the radiomic features within the lesion area were extracted for each image modality. The calculations were done using pyradiomics software and a total of 4,744 stroke-related imaging features were automatically calculated. Next, feature selection based on recursive feature elimination was used for each modality and three radiomic features were extracted from each modality plus one feature from the lesion mask, for a total of 16 radiomic features. At last, five machine learning (ML) models were trained and tested to predict stroke prognosis, calculate the received operating characteristic (ROC) curves and other parameters, evaluate the performance of the models and validate their predictive efficacy by five-fold cross-validation. RESULTS Sixteen radiomic features were selected to construct the ML models for prognostic classification. By five-fold cross-validation, light gradient boosting machine (LightGBM) model-based muti-modal MRI radiomic features performed best in binary prognostic classification with accuracy of 0.831, sensitivity of 0.739, specificity of 0.902, F1-score of 0.788 and an area under the curve (AUC) of 0.902. CONCLUSION The ML models based on muti-modal MRI radiomics are of high value for predicting clinical outcomes in acute stroke patients.
Collapse
Affiliation(s)
- Huan Yu
- Department of Radiology, Liangxiang Hospital, Beijing, China
| | - Zhenwei Wang
- Department of Radiology, Liangxiang Hospital, Beijing, China
| | - Yiqing Sun
- Department of Radiology, Liangxiang Hospital, Beijing, China
| | - Wenwei Bo
- Department of Radiology, Liangxiang Hospital, Beijing, China
| | - Kai Duan
- Department of Radiology, Liangxiang Hospital, Beijing, China
| | - Chunhua Song
- Department of Radiology, Liangxiang Hospital, Beijing, China
| | - Yi Hu
- Department of Radiology, Liangxiang Hospital, Beijing, China
| | - Jie Zhou
- Department of Radiology, Liangxiang Hospital, Beijing, China
| | - Zizhang Mu
- Department of Neurology, Liangxiang Hospital, Beijing, China
| | - Ning Wu
- Department of Medical Imaging, Yanjing Medical College, Capital Medical University, Beijing, China
| |
Collapse
|
37
|
Fan R, Huang X, Nian X, Ou Z, Zhou J, Zhang J, Zeng P, Zhao W, Deng J, Chen W, Chen S, Duan K, Chen Y, Li X, Zhang J, Yang X. Safety and immunogenicity of a quadrivalent influenza vaccine in adults aged 60 years or above: a phase III randomized controlled clinical study. Hum Vaccin Immunother 2021; 18:1-9. [PMID: 34473607 PMCID: PMC8920214 DOI: 10.1080/21645515.2021.1967041] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
Abstract
To control seasonal influenza epidemics in elders, a quadrivalent, inactivated, split-virion influenza vaccine (IIV4) comprising A and B lineages is produced for young individuals and adults aged ≥60 years. In this phase III, randomized, double-blind, active-controlled trial, we compared safety and immunogenicity of IIV4 with a licensed quadrivalent inactivated vaccine (IIV4-HL) produced by Hualan Biological Engineering during the 2019 influenza season. Participants were randomly assigned to receive IIV4 (n = 959) or IIV4-HL (n = 959). Compared to IIV4-HL, geometric mean titers (GMT) of hemagglutination inhibition (HAI) titers and seroconversion rate (SCR) of IIV4 demonstrated better antibody responses in A lineages (H1N1 and H3N2) (P < .01) and equivalent antibody responses in B lineages (B/Yamagata and B/Victoria) (P > .01) in both age groups. After immunization, IIV4 provided a satisfactory SCR and seroprotection rate (SPR) in elders. No discernible variation in immunogenicity was observed between the two age cohorts. In both age groups, IIV4 and IIV4-HL recipients experienced similar levels of solicited and unsolicited adverse events (AEs), and the incidence of AEs was low in both vaccine groups. Most AEs were of mild-to-moderate severity and no grade 3 AEs in IIV4 group, but AEs in adults aged 60–65 were little higher than in adults over 65 years in IIV4 and IIV4-HL groups (IIV4: 14.66% vs. 10.36%; IIV4-HL:14.67% vs. 11.43%). Totally, IIV4 was generally well tolerated and induced high antibody titers against all four influenza strains in elderly, making it a compelling alternative for the elderly aged ≥60 years. Trial registration: Clinical Trials.gov: 2015L00649-2.
Collapse
Affiliation(s)
- Renfeng Fan
- Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, China
| | - Xiaoyuan Huang
- Wuhan Institute of Biological Products Co. Ltd, Wuhan, China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, China
| | - Xuanxuan Nian
- Wuhan Institute of Biological Products Co. Ltd, Wuhan, China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, China
| | - Zhiqiang Ou
- Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, China
| | - Jian Zhou
- Gaozhou Center for Disease Control and Prevention, Gaozhou, China
| | - Jiayou Zhang
- Wuhan Institute of Biological Products Co. Ltd, Wuhan, China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, China
| | - Peiyu Zeng
- Gaozhou Center for Disease Control and Prevention, Gaozhou, China
| | - Wei Zhao
- Wuhan Institute of Biological Products Co. Ltd, Wuhan, China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, China
| | - Jinglong Deng
- Gaozhou Center for Disease Control and Prevention, Gaozhou, China
| | - Wei Chen
- Wuhan Institute of Biological Products Co. Ltd, Wuhan, China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, China
| | - Shaomin Chen
- Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, China
| | - Kai Duan
- Wuhan Institute of Biological Products Co. Ltd, Wuhan, China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, China
| | - Yingshi Chen
- Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, China
| | - Xinguo Li
- Wuhan Institute of Biological Products Co. Ltd, Wuhan, China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, China
| | - Jikai Zhang
- Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, China
| | - Xiaoming Yang
- National Engineering Technology Research Center of Combined Vaccines, Wuhan, China.,China National Biotec Group Company Limited, Beijing, China
| |
Collapse
|
38
|
Guo W, Duan K, Zhang Y, Yuan Z, Zhang YB, Wang Z, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang W, Yang Y, Chen W, Gao X, You W, Wang XW, Shi Z, Wang Y, Yang XQ, Zhang L, Huang L, Wang Q, Lu J, Yang YL, Guo J, Zhou W, Wan X, Wu C, Wang W, Du J, Nian X, Li XH, Huang S, Shen S, Xia S, Pan A, Yang X. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial. EClinicalMedicine 2021; 38:101010. [PMID: 34250456 PMCID: PMC8260504 DOI: 10.1016/j.eclinm.2021.101010] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/15/2021] [Revised: 06/11/2021] [Accepted: 06/16/2021] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND We aimed to assess the safety and immunogenicity of an inactivated vaccine against COVID-19 in Chinese adults aged ≥18 years. METHODS This is an ongoing randomized, double-blind, placebo-controlled, phase 1/2 clinical trial among healthy adults aged ≥18 years in Henan Province, China. Participants (n = 336 in 18-59 age group and n = 336 in ≥60 age group) were enrolled between April 12 and May 17 2020, and were equally randomized to receive vaccine or placebo (aluminum hydroxide adjuvant) in a three-dose schedule of 2·5, 5, or 10 µg on days 0, 28, and 56. Another 448 adults aged 18-59 years were equally allocated to four groups (a one-dose schedule of 10 µg, and two-dose schedules of 5 µg on days 0 and 14/21/28) and received vaccine or placebo (ratio 3:1 within each group). The primary outcomes were 7-day post-injection adverse reactions and neutralizing antibody titres on days 28 and 90 after the whole-course vaccination. Trial registration: www.chictr.org.cn #ChiCTR2000031809. FINDINGS The 7-day adverse reactions occurred in 4·8% to 32·1% of the participants in various groups, and most adverse reactions were mild, transient, and self-limiting. Twenty participants reported 68 serious adverse events which were judged to be unrelated to the vaccine. The 90-day post-injection geometric mean titres of neutralizing antibody ranged between 87 (95% CI: 61-125) and 129 (99-169) for three-dose schedule among younger and older adults; 20 (14-27), 53 (38-75), and 44 (32-61) in 5 µg days 0 and 14/21/28 groups, respectively, and 7 (6-9) in one-dose 10 µg group. There were no detectable antibody responses in all placebo groups. INTERPRETATION The inactivated vaccine against COVID-19 was well tolerated and immunogenic in both younger and older adults. The two-dose schedule of 5 µg on days 0 and 21/28 and three-dose schedules on days 0, 28, and 56 could be further evaluated for long-term safety and efficacy in the phase 3 trials.
Collapse
Affiliation(s)
- Wanshen Guo
- Henan Province Centre for Disease Control and Prevention, Zhengzhou, Henan, China
| | - Kai Duan
- National Engineering Technology Research Centre for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Yuntao Zhang
- China National Biotec Group Company Limited, Beijing, China
| | - Zhiming Yuan
- Chinese Academy of Sciences Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Centre for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China
| | - Yan-Bo Zhang
- Department of Epidemiology and Biostatistics, Ministry of Education Key Laboratory of Environment and Health and State Key Laboratory of Environmental Health (incubation), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Zejun Wang
- National Engineering Technology Research Centre for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Dongyang Zhao
- Henan Province Centre for Disease Control and Prevention, Zhengzhou, Henan, China
| | - Huajun Zhang
- Chinese Academy of Sciences Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Centre for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China
| | - Zhiqiang Xie
- Henan Province Centre for Disease Control and Prevention, Zhengzhou, Henan, China
| | - Xinguo Li
- National Engineering Technology Research Centre for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Cheng Peng
- Chinese Academy of Sciences Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Centre for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China
| | - Wei Zhang
- Henan Province Centre for Disease Control and Prevention, Zhengzhou, Henan, China
| | - Yunkai Yang
- China National Biotec Group Company Limited, Beijing, China
| | - Wei Chen
- National Engineering Technology Research Centre for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Xiaoxiao Gao
- Chinese Academy of Sciences Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Centre for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China
| | - Wangyang You
- Henan Province Centre for Disease Control and Prevention, Zhengzhou, Henan, China
| | - Xue-Wei Wang
- China National Biotec Group Company Limited, Beijing, China
| | - Zhengli Shi
- Chinese Academy of Sciences Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Centre for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China
| | - Yanxia Wang
- Henan Province Centre for Disease Control and Prevention, Zhengzhou, Henan, China
| | - Xu-Qin Yang
- China National Biotec Group Company Limited, Beijing, China
| | - Lianghao Zhang
- National Engineering Technology Research Centre for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Lili Huang
- Henan Province Centre for Disease Control and Prevention, Zhengzhou, Henan, China
| | - Qian Wang
- China National Biotec Group Company Limited, Beijing, China
| | - Jia Lu
- National Engineering Technology Research Centre for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Yong-Li Yang
- Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China
| | - Jing Guo
- National Engineering Technology Research Centre for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Wei Zhou
- National Engineering Technology Research Centre for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Xin Wan
- National Engineering Technology Research Centre for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Cong Wu
- National Engineering Technology Research Centre for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Wenhui Wang
- National Engineering Technology Research Centre for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Jianhui Du
- National Engineering Technology Research Centre for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Xuanxuan Nian
- National Engineering Technology Research Centre for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Xing-Hang Li
- National Engineering Technology Research Centre for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Shihe Huang
- National Engineering Technology Research Centre for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Shuo Shen
- National Engineering Technology Research Centre for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Shengli Xia
- Henan Province Centre for Disease Control and Prevention, Zhengzhou, Henan, China
| | - An Pan
- Department of Epidemiology and Biostatistics, Ministry of Education Key Laboratory of Environment and Health and State Key Laboratory of Environmental Health (incubation), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Xiaoming Yang
- National Engineering Technology Research Centre for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
- China National Biotec Group Company Limited, Beijing, China
| |
Collapse
|
39
|
Pan Y, Du J, Liu J, Wu H, Gui F, Zhang N, Deng X, Song G, Li Y, Lu J, Wu X, Zhan S, Jing Z, Wang J, Yang Y, Liu J, Chen Y, Chen Q, Zhang H, Hu H, Duan K, Wang M, Wang Q, Yang X. Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries. Cell Discov 2021; 7:57. [PMID: 34315862 PMCID: PMC8315086 DOI: 10.1038/s41421-021-00295-w] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2021] [Accepted: 06/22/2021] [Indexed: 12/28/2022] Open
Abstract
As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to threaten public health worldwide, the development of effective interventions is urgently needed. Neutralizing antibodies (nAbs) have great potential for the prevention and treatment of SARS-CoV-2 infection. In this study, ten nAbs were isolated from two phage-display immune libraries constructed from the pooled PBMCs of eight COVID-19 convalescent patients. Eight of them, consisting of heavy chains encoded by the immunoglobulin heavy-chain gene-variable region (IGHV)3-66 or IGHV3-53 genes, recognized the same epitope on the receptor-binding domain (RBD), while the remaining two bound to different epitopes. Among the ten antibodies, 2B11 exhibited the highest affinity and neutralization potency against the original wild-type (WT) SARS-CoV-2 virus (KD = 4.76 nM for the S1 protein, IC50 = 6 ng/mL for pseudoviruses, and IC50 = 1 ng/mL for authentic viruses), and potent neutralizing ability against B.1.1.7 pseudoviruses. Furthermore, 1E10, targeting a distinct epitope on RBD, exhibited different neutralization efficiency against WT SARS-CoV-2 and its variants B.1.1.7, B.1.351, and P.1. The crystal structure of the 2B11-RBD complexes revealed that the epitope of 2B11 highly overlaps with the ACE2-binding site. The in vivo experiment of 2B11 using AdV5-hACE2-transduced mice showed encouraging therapeutic and prophylactic efficacy against SARS-CoV-2. Taken together, our results suggest that the highly potent SARS-CoV-2-neutralizing antibody, 2B11, could be used against the WT SARS-CoV-2 and B.1.1.7 variant, or in combination with a different epitope-targeted neutralizing antibody, such as 1E10, against SARS-CoV-2 variants.
Collapse
Affiliation(s)
- Yongbing Pan
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Jianhui Du
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Jia Liu
- State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China
| | - Hai Wu
- Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, China
- University of Chinese Academy of Sciences, Beijing, China
| | - Fang Gui
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Nan Zhang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Xiaojie Deng
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Gang Song
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Yufeng Li
- State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China
| | - Jia Lu
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Xiaoli Wu
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - ShanShan Zhan
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Zhaofei Jing
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Jiong Wang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Yimin Yang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Jianbang Liu
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Ying Chen
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Qin Chen
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China
| | - Huanyu Zhang
- State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China
| | - Hengrui Hu
- State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China
| | - Kai Duan
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China.
| | - Manli Wang
- State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China.
| | - Qisheng Wang
- Shanghai Synchrotron Radiation Facility, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China.
| | - Xiaoming Yang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, Hubei, China.
- China National Biotec Group Company Limited, Beijing, China.
| |
Collapse
|
40
|
Duan K, Jang GH, Grant RC, Wilson JM, Notta F, O'Kane GM, Knox JJ, Gallinger S, Fischer S. The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer. Sci Rep 2021; 11:14951. [PMID: 34294813 PMCID: PMC8298486 DOI: 10.1038/s41598-021-94544-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Accepted: 07/13/2021] [Indexed: 12/24/2022] Open
Abstract
Combination chemotherapy, either modified FOLFIRINOX (mFFX) or gemcitabine-nabpaclitaxel, are used in the treatment of most patients with advanced pancreatic ductal adenocarcinoma (PDAC), yet robust biomarkers of outcome are currently lacking to guide regimen selection. Here, we tested GATA6 immunohistochemistry (IHC) as a putative biomarker in advanced PDAC. GATA6 is a transcription factor in normal pancreas development. Two pathologists, blinded to clinical and molecular data, independently assessed GATA6 IHC in biopsy specimens of 130 patients with advanced PDAC, in 2 distinct phases (without and with computer assistance using the open source software QuPath). Low GATA6 IHC expression was associated with shorter overall survival [median OS 6.2 months for patients with GATA6 low tumors vs. 11.5 months for patients with GATA6 high tumors, HR 1.66 (95% CI 1.15-2.40), P = 0.007]. Progression appears to be higher in GATA6-low tumors compared to GATA6-high tumors in patients treated with mFFX (P = 0.024) but not in patients treated with gemcitabine regimens. GATA6 IHC expression was significantly associated with molecular subtypes (P = 0.0003). Digital assistance markedly improved interrater concordance (Cohen's kappa scores of 0.32 vs. 0.95). Our results provide strong evidence that GATA6 IHC can be used as a single biomarker in the clinic to predict clinical outcome in advanced PDAC, warranting further investigation in prospective clinical trials. These results provide the basis for an improved classification of PDAC and future biomarker design using digital pathology workflow.
Collapse
Affiliation(s)
- Kai Duan
- Laboratory Medicine Program, University Health Network, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada.
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
| | - Gun-Ho Jang
- Ontario Institute for Cancer Research, Toronto, ON, Canada
| | - Robert C Grant
- Ontario Institute for Cancer Research, Toronto, ON, Canada
- Wallace McCain Centre for Pancreatic Cancer, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - Julie M Wilson
- Ontario Institute for Cancer Research, Toronto, ON, Canada
| | - Faiyaz Notta
- Ontario Institute for Cancer Research, Toronto, ON, Canada
- Division of Research, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - Grainne M O'Kane
- Ontario Institute for Cancer Research, Toronto, ON, Canada
- Wallace McCain Centre for Pancreatic Cancer, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - Jennifer J Knox
- Wallace McCain Centre for Pancreatic Cancer, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - Steven Gallinger
- Ontario Institute for Cancer Research, Toronto, ON, Canada
- Wallace McCain Centre for Pancreatic Cancer, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
- Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada
- Hepatobiliary/Pancreatic Surgical Oncology Program, University Health Network, Toronto, ON, Canada
| | - Sandra Fischer
- Laboratory Medicine Program, University Health Network, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada.
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
- Laboratory Medicine Program, University Health Network, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada.
| |
Collapse
|
41
|
Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, Al Nusair M, Hassany M, Jawad JS, Abdalla J, Hussein SE, Al Mazrouei SK, Al Karam M, Li X, Yang X, Wang W, Lai B, Chen W, Huang S, Wang Q, Yang T, Liu Y, Ma R, Hussain ZM, Khan T, Saifuddin Fasihuddin M, You W, Xie Z, Zhao Y, Jiang Z, Zhao G, Zhang Y, Mahmoud S, ElTantawy I, Xiao P, Koshy A, Zaher WA, Wang H, Duan K, Pan A, Yang X. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA 2021; 326:35-45. [PMID: 34037666 PMCID: PMC8156175 DOI: 10.1001/jama.2021.8565] [Citation(s) in RCA: 504] [Impact Index Per Article: 168.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
IMPORTANCE Although effective vaccines against COVID-19 have been developed, additional vaccines are still needed. OBJECTIVE To evaluate the efficacy and adverse events of 2 inactivated COVID-19 vaccines. DESIGN, SETTING, AND PARTICIPANTS Prespecified interim analysis of an ongoing randomized, double-blind, phase 3 trial in the United Arab Emirates and Bahrain among adults 18 years and older without known history of COVID-19. Study enrollment began on July 16, 2020. Data sets used for the interim analysis of efficacy and adverse events were locked on December 20, 2020, and December 31, 2020, respectively. INTERVENTIONS Participants were randomized to receive 1 of 2 inactivated vaccines developed from SARS-CoV-2 WIV04 (5 µg/dose; n = 13 459) and HB02 (4 µg/dose; n = 13 465) strains or an aluminum hydroxide (alum)-only control (n = 13 458); they received 2 intramuscular injections 21 days apart. MAIN OUTCOMES AND MEASURES The primary outcome was efficacy against laboratory-confirmed symptomatic COVID-19 14 days following a second vaccine dose among participants who had no virologic evidence of SARS-CoV-2 infection at randomization. The secondary outcome was efficacy against severe COVID-19. Incidence of adverse events and reactions was collected among participants who received at least 1 dose. RESULTS Among 40 382 participants randomized to receive at least 1 dose of the 2 vaccines or alum-only control (mean age, 36.1 years; 32 261 [84.4%] men), 38 206 (94.6%) who received 2 doses, contributed at least 1 follow-up measure after day 14 following the second dose, and had negative reverse transcriptase-polymerase chain reaction test results at enrollment were included in the primary efficacy analysis. During a median (range) follow-up duration of 77 (1-121) days, symptomatic COVID-19 was identified in 26 participants in the WIV04 group (12.1 [95% CI, 8.3-17.8] per 1000 person-years), 21 in the HB02 group (9.8 [95% CI, 6.4-15.0] per 1000 person-years), and 95 in the alum-only group (44.7 [95% CI, 36.6-54.6] per 1000 person-years), resulting in a vaccine efficacy, compared with alum-only, of 72.8% (95% CI, 58.1%-82.4%) for WIV04 and 78.1% (95% CI, 64.8%-86.3%) for HB02 (P < .001 for both). Two severe cases of COVID-19 occurred in the alum-only group and none occurred in the vaccine groups. Adverse reactions 7 days after each injection occurred in 41.7% to 46.5% of participants in the 3 groups; serious adverse events were rare and similar in the 3 groups (WIV04: 64 [0.5%]; HB02: 59 [0.4%]; alum-only: 78 [0.6%]). CONCLUSIONS AND RELEVANCE In this prespecified interim analysis of a randomized clinical trial, treatment of adults with either of 2 inactivated SARS-CoV-2 vaccines significantly reduced the risk of symptomatic COVID-19, and serious adverse events were rare. Data collection for final analysis is pending. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT04510207; Chinese Clinical Trial Registry: ChiCTR2000034780.
Collapse
Affiliation(s)
- Nawal Al Kaabi
- Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates
| | - Yuntao Zhang
- China National Biotec Group Company Limited, Beijing, China
| | - Shengli Xia
- Henan Province Center for Disease Control and Prevention, Zhengzhou, Henan, China
| | - Yunkai Yang
- China National Biotec Group Company Limited, Beijing, China
| | - Manaf M. Al Qahtani
- Bahrain Defence Force Royal Medical Services, Military Hospital, Kingdom of Bahrain
| | | | | | | | | | - Jehad Abdalla
- Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates
| | - Salah Eldin Hussein
- Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates
| | - Shamma K. Al Mazrouei
- Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates
| | - Maysoon Al Karam
- Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates
| | - Xinguo Li
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co, Ltd, Wuhan, Hubei, China
| | - Xuqin Yang
- China National Biotec Group Company Limited, Beijing, China
| | - Wei Wang
- Beijing Institute of Biological Products Co, Ltd, Beijing, China
| | - Bonan Lai
- China National Biotec Group Company Limited, Beijing, China
| | - Wei Chen
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co, Ltd, Wuhan, Hubei, China
| | - Shihe Huang
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co, Ltd, Wuhan, Hubei, China
| | - Qian Wang
- China National Biotec Group Company Limited, Beijing, China
| | - Tian Yang
- China National Biotec Group Company Limited, Beijing, China
| | - Yang Liu
- China National Biotec Group Company Limited, Beijing, China
| | - Rui Ma
- Beijing Institute of Biological Products Co, Ltd, Beijing, China
| | - Zaidoon M. Hussain
- Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates
| | - Tehmina Khan
- Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates
| | | | - Wangyang You
- Henan Province Center for Disease Control and Prevention, Zhengzhou, Henan, China
| | - Zhiqiang Xie
- Henan Province Center for Disease Control and Prevention, Zhengzhou, Henan, China
| | - Yuxiu Zhao
- Beijing Institute of Biological Products Co, Ltd, Beijing, China
| | - Zhiwei Jiang
- Beijing Key-Tech Statistical Consulting Co, Ltd, Beijing, China
| | - Guoqing Zhao
- Beijing Key-Tech Statistical Consulting Co, Ltd, Beijing, China
| | - Yanbo Zhang
- Department of Epidemiology and Biostatistics, Ministry of Education Key Laboratory of Environment and Health and State Key Laboratory of Environmental Health (incubation), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | | | | | - Peng Xiao
- G42 Healthcare, Abu Dhabi, United Arab Emirates
| | - Ashish Koshy
- Department of Epidemiology and Biostatistics, Ministry of Education Key Laboratory of Environment and Health and State Key Laboratory of Environmental Health (incubation), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | | | - Hui Wang
- Beijing Institute of Biological Products Co, Ltd, Beijing, China
| | - Kai Duan
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co, Ltd, Wuhan, Hubei, China
| | - An Pan
- Department of Epidemiology and Biostatistics, Ministry of Education Key Laboratory of Environment and Health and State Key Laboratory of Environmental Health (incubation), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Xiaoming Yang
- China National Biotec Group Company Limited, Beijing, China
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co, Ltd, Wuhan, Hubei, China
| |
Collapse
|
42
|
Wu ZW, Li QL, Zhou HS, Duan K, Gao Z, Zhang XJ, Jiang ZJ, Hao ZY, Jin F, Bai X, Li Q, Xu GL, Zhao YL, Yang XM. Safety and immunogenicity of a novel oral hexavalent rotavirus vaccine:a phase I clinical trial. Hum Vaccin Immunother 2021; 17:2311-2318. [PMID: 33545015 PMCID: PMC8189138 DOI: 10.1080/21645515.2020.1861874] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2020] [Revised: 11/25/2020] [Accepted: 12/02/2020] [Indexed: 01/18/2023] Open
Abstract
Background Rotavirus infections, prevalent in human populations, are caused mostly by group A viruses. Immunization against rotaviruses in infancy is currently the most effective and economical strategy to prevent rotavirus infection. This study evaluated the safety of a novel hexavalent rotavirus vaccine and analyzed its dose and immunogenicity.Methods This randomized, double-blinded, placebo-controlled phase I clinical trial enrolled healthy adults, toddlers, and infants in Zhengding County, Hebei Province, northern China. 40 adults and 40 children were assigned in a 2:1:1 ratio to receive one vaccine dose, placebo 1, and placebo 2, respectively. 120 6-12 week old infants were assigned equivalently into 3 groups. The infants in each group were assigned in a 2:1:1 ratio to receive three doses of vaccine, placebo 1, and placebo 2, at a 28-day interval. Adverse events (AEs) until 28 days after each dose and serious adverse events (SAEs) until 6 months after the third dose were reported. Virus shedding until 14 days after each dose in infants was tested. Geometric mean concentrations (GMCs) and seroconversion rates were measured for anti-rotavirus IgA by using an enzyme-linked immunosorbent assay (ELISA).Results The solicited and unsolicited AE frequencies and laboratory indexes were similar among the treatment groups. No vaccine-related SAEs were reported. The average percentage of rotavirus vaccine shedding in the infant vaccine groups was 5.00%. The post-3rd dose anti-rotavirus IgA antibody geometric mean concentrations (GMC) and seroconversion rate were higher in the vaccine groups than in the placebo groups.Conclusions The novel oral hexavalent rotavirus vaccine was generally well-tolerated in all adults, toddlers and infants, and the vaccine was immunogenic in infants.
Collapse
Affiliation(s)
- Zhi-Wei Wu
- Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People’s Republic of China
| | - Qing-Liang Li
- Wuhan Institute of Biological Products Co., Ltd., Wuhan, People’s Republic of China
| | - Hai-Song Zhou
- Zhengding County Center for Disease Control and Prevention, Zhengding, People’s Republic of China
| | - Kai Duan
- Wuhan Institute of Biological Products Co., Ltd., Wuhan, People’s Republic of China
| | - Zhao Gao
- Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People’s Republic of China
| | - Xin-Jiang Zhang
- Zhengding County Center for Disease Control and Prevention, Zhengding, People’s Republic of China
| | - Zhi-Jun Jiang
- Wuhan Institute of Biological Products Co., Ltd., Wuhan, People’s Republic of China
| | - Zhi-Yong Hao
- Zhengding County Center for Disease Control and Prevention, Zhengding, People’s Republic of China
| | - Fei Jin
- Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People’s Republic of China
| | - Xuan Bai
- Wuhan Institute of Biological Products Co., Ltd., Wuhan, People’s Republic of China
| | - Qi Li
- Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People’s Republic of China
| | - Ge-Lin Xu
- Wuhan Institute of Biological Products Co., Ltd., Wuhan, People’s Republic of China
| | - Yu-Liang Zhao
- Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People’s Republic of China
| | - Xiao-Ming Yang
- Wuhan Institute of Biological Products Co., Ltd., Wuhan, People’s Republic of China
| |
Collapse
|
43
|
Grant RC, Duan K, Jackson R, Greenhalf W, Costello-Goldring E, Ghaneh P, Halloran C, Palmer D, Hackert T, Buchler M, Hutchison S, Ramotar S, Dodd A, Wilson J, Notta F, O'Kane G, Knox J, Neoptolemos J, Gallinger S, Fischer S. Abstract 1193: Digital quantification of GATA6 expression from immunohistochemistry is associated with overall survival after surgery for pancreatic cancer in the ESPAC trials. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-1193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: GATA6, a transcription factor involved in pancreaticogenesis, correlates with major transcriptomic subtypes of pancreatic cancer, and early evidence suggests a potential role as a prognostic biomarker. In this study, we tested whether semi-automated digital quantification of GATA6 immunohistochemistry (IHC) was associated with overall survival (OS) after surgical resection of pancreatic cancer in randomized trials of adjuvant chemotherapy.
Materials and Methods: Tissue microarrays of pancreatic adenocarcinoma specimens were stained for GATA6 expression using IHC. Specimens came from patients in the ESPAC-3 and ESPAC-4 randomized phase III trials comparing adjuvant chemotherapy regimens. Two pathologists blinded to clinical data independently assessed GATA6 protein expression in cores using a customized computer algorithm from the open-source digital pathology software QuPath. Briefly, the digital assistant provided GATA6 IHC semiquantitative scores (0-4) for individual cells, which were made available to the pathologist for review. This semi-automated digital quantification of GATA6 expression was compared to manual quantification as previously reported (Grant et al., AACR Pancreatic Cancer, 2020). Concordance between pathologists across tissue cores was calculated using a weighted kappa statistic for scores 0 through 4, and an unweighted kappa statistic for high (3-4) and low (0-2) expression levels. Discrepancies were resolved through consensus. Median OS was estimated in GATA6 high and low subgroups using Kaplan-Meier curves. OS was compared using Cox proportional hazard regressions adjusting for adjuvant chemotherapy treatment, lymph node status, and post-operative CA-19-9.
Results: GATA6 expression was quantified in 230 patients using the semi-automated digital and manual approaches. Inter-observer concordance markedly improved with digital assistance compared to the manual approach (weighted kappa statistic across all scores 0.69 versus 0.41, unweighted kappa statistic comparing high and low expression 0.71 versus 0.25). GATA6 expression measured using the semi-automated digital approach was significantly associated with OS: median OS was 25.7 months in GATA6 low cancers versus 42.4 months in GATA6 high cancers, with an adjusted hazard ratio of 1.58 (95% confidence interval 1.10-2.28, P=0.014).
Conclusion: GATA6 IHC is a prognostic biomarker for pancreatic cancers treated with surgical resection and adjuvant chemotherapy that can be consistently and reliably quantified using digital assistance.
Citation Format: Robert C. Grant, Kai Duan, Richard Jackson, William Greenhalf, Eithne Costello-Goldring, Paula Ghaneh, Christopher Halloran, Daniel Palmer, Thilo Hackert, Markus Buchler, Shawn Hutchison, Stephanie Ramotar, Anna Dodd, Julie Wilson, Faiyaz Notta, Grainne O'Kane, Jennifer Knox, John Neoptolemos, Steven Gallinger, Sandra Fischer. Digital quantification of GATA6 expression from immunohistochemistry is associated with overall survival after surgery for pancreatic cancer in the ESPAC trials [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1193.
Collapse
Affiliation(s)
| | - Kai Duan
- 2University Health Network, Toronto, Ontario, Canada
| | | | | | | | - Paula Ghaneh
- 3University of Liverpool, Liverpool, United Kingdom
| | | | | | | | | | | | | | - Anna Dodd
- 1Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| | - Julie Wilson
- 5Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - Faiyaz Notta
- 5Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - Grainne O'Kane
- 1Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| | - Jennifer Knox
- 1Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| | | | | | - Sandra Fischer
- 1Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| |
Collapse
|
44
|
Wu J, Zhang L, Zhang Y, Wang H, Ding R, Nie J, Li Q, Liu S, Yu Y, Yang X, Duan K, Qu X, Wang Y, Huang W. The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom. Front Immunol 2021; 12:687869. [PMID: 34220844 PMCID: PMC8247764 DOI: 10.3389/fimmu.2021.687869] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Accepted: 05/24/2021] [Indexed: 11/13/2022] Open
Abstract
To determine whether the neutralization activity of monoclonal antibodies, convalescent sera and vaccine-elicited sera was affected by the top five epidemic SARS-CoV-2 variants in the UK, including D614G+L18F+A222V, D614G+A222V, D614G+S477N, VOC-202012/01(B.1.1.7) and D614G+69-70del+N439K, a pseudovirus-neutralization assay was performed to evaluate the relative neutralization titers against the five SARS-CoV-2 variants and 12 single deconvolution mutants based on the variants. In this study, 18 monoclonal antibodies, 10 sera from convalescent COVID-19 patients, 10 inactivated-virus vaccine-elicited sera, 14 mRNA vaccine-elicited sera, nine RBD-immunized mouse sera, four RBD-immunized horse sera, and four spike-encoding DNA-immunized guinea pig sera were tested and analyzed. The N501Y, N439K, and S477N mutations caused immune escape from nine of 18 mAbs. However, the convalescent sera, inactivated virus vaccine-elicited sera, mRNA vaccine-elicited sera, spike DNA-elicited sera, and recombinant RBD protein-elicited sera could still neutralize these variants (within three-fold changes compared to the reference D614G variant). The neutralizing antibody responses to different types of vaccines were different, whereby the response to inactivated-virus vaccine was similar to the convalescent sera.
Collapse
Affiliation(s)
- Jiajing Wu
- Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China
- Wuhan Institute of Biological Products, Hubei, China
| | - Li Zhang
- Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China
| | - Yue Zhang
- Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China
- National Vaccine & Serum Institute, Beijing, China
| | - Haixin Wang
- Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China
- Department of Pharmaceutical Engineering, College of Life Science and Technology, Dalian University, Dalian, China
| | - Ruxia Ding
- Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China
| | - Jianhui Nie
- Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China
| | - Qianqian Li
- Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China
- Graduate School of Peking Union Medical College, Beijing, China
| | - Shuo Liu
- Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China
| | - Yongxin Yu
- Wuhan Institute of Biological Products, Hubei, China
- Department of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, China
| | - Xiaoming Yang
- China National Biotec Group Company Limited, Beijing, China
| | - Kai Duan
- Wuhan Institute of Biological Products, Hubei, China
- National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, China
| | - Xiaowang Qu
- Translational Medicine Institute, First People’s Hospital of Chenzhou, University of South China, Chenzhou, China
| | - Youchun Wang
- Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China
| | - Weijin Huang
- Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China
| |
Collapse
|
45
|
Paller A, Tham K, Lefferdink R, Duan K, Lim S, Ibler E, Chima M, Kim H, Wu B, Abu-Zayed H, Rangel S, Guttman-Yassky E, Lee B, Common J. 206 The distinct skin microbiota of congenital ichthyoses. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
46
|
Nie J, Li Q, Zhang L, Cao Y, Zhang Y, Li T, Wu J, Liu S, Zhang M, Zhao C, Liu H, Nie L, Qin H, Wang M, Lu Q, Li X, Liu J, Liang H, Jiang T, Duan K, Yang X, Shen Y, Huang W, Wang Y. Functional comparison of SARS-CoV-2 with closely related pangolin and bat coronaviruses. Cell Discov 2021; 7:21. [PMID: 33824288 PMCID: PMC8022302 DOI: 10.1038/s41421-021-00256-3] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2021] [Accepted: 03/02/2021] [Indexed: 01/02/2023] Open
Abstract
The origin and intermediate host for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is yet to be determined. Coronaviruses found to be closely related to SARS-CoV-2 include RaTG13 derived from bat and two clusters (PCoV-GD and PCoV-GX) of coronaviruses identified in pangolin. Here, we studied the infectivity and antigenicity patterns of SARS-CoV-2 and the three related coronaviruses. Compared with the other three viruses, RaTG13 showed almost no infectivity to a variety of cell lines. The two pangolin coronaviruses and SARS-CoV-2 showed similar infectious activity. However, in SARS-CoV-2-susceptible cell lines, the pangolin coronaviruses presented even higher infectivity. The striking difference between the SARS-CoV-2 and pangolin coronaviruses is that the latter can infect porcine cells, which could be partially attributed to an amino acid difference at the position of 498 of the spike protein. The infection by SARS-CoV-2 was mainly mediated by Furin and TMPRSS2, while PCoV-GD and PCoV-GX mainly depend on Cathepsin L. Extensive cross-neutralization was found between SARS-CoV-2 and PCoV-GD. However, almost no cross-neutralization was observed between PCoV-GX and SARS-CoV-2 or PCoV-GD. More attention should be paid to pangolin coronaviruses and to investigate the possibility of these coronaviruses spreading across species to become zoonoses among pigs or humans.
Collapse
Affiliation(s)
- Jianhui Nie
- Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, China
| | - Qianqian Li
- Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, China
- Graduate School of Peking Union Medical College, No. 9 Dongdan Santiao, Dongcheng District, Beijing 100730, China
| | - Li Zhang
- Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, China
| | - Yang Cao
- Center of Growth, Metabolism and Aging, Key Laboratory of Bio-Resource and Eco-Environment of Ministry of Education, College of Life Sciences, Sichuan University, Chengdu, Sichuan 610065, China
| | - Yue Zhang
- Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, China
| | - Tao Li
- Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, China
| | - Jiajing Wu
- Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, China
| | - Shuo Liu
- Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, China
| | - Mengyi Zhang
- Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, China
| | - Chenyan Zhao
- Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, China
| | - Huan Liu
- Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, China
| | - Lingling Nie
- Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, China
| | - Haiyang Qin
- Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, China
| | - Meng Wang
- Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, China
| | - Qiong Lu
- Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, China
| | - Xiaoyu Li
- Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, China
| | - Junkai Liu
- Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, China
| | - Haoyu Liang
- Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, China
| | - Taijiao Jiang
- Center for Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China
- Suzhou Institute of Systems Medicine, Suzhou, Jiangsu 215123, China
| | - Kai Duan
- China National Biotec Group Company Limited, Beijing 100029, China
| | - Xiaoming Yang
- China National Biotec Group Company Limited, Beijing 100029, China
| | - Yuelei Shen
- Beijing Biocytogen Co., Ltd., Beijing 101111, China
| | - Weijin Huang
- Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, China.
| | - Youchun Wang
- Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No. 31 Huatuo Street, Daxing District, Beijing 102629, China.
- Graduate School of Peking Union Medical College, No. 9 Dongdan Santiao, Dongcheng District, Beijing 100730, China.
| |
Collapse
|
47
|
Yang J, Huang X, Zhang J, Fan R, Zhao W, Han T, Duan K, Li X, Zeng P, Deng J, Zhang J, Yang X. Sex-specific differences of humoral immunity and transcriptome diversification in older adults vaccinated with inactivated quadrivalent influenza vaccines. Aging (Albany NY) 2021; 13:9801-9819. [PMID: 33744852 PMCID: PMC8064175 DOI: 10.18632/aging.202733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2020] [Accepted: 02/16/2021] [Indexed: 11/25/2022]
Abstract
Clinical data showed sex variability in the immune response to influenza vaccination, this study aimed to investigate differentially expressed genes (DEGs) that contribute to sex-bias immunity to quadrivalent inactivated influenza vaccines (QIVs) in the elderly. 60 healthy adults aged 60-80 yrs were vaccinated with QIVs, and gene expression was analyzed before and after vaccination. The humoral immunity was analyzed by HAI assay, and the correlation of gene expression patterns of two sex groups with humoral immunity was analyzed. The DEGs involved in type I interferon signaling pathway and complement activation of classical pathway were upregulated within 3 days in females. At Day 28, the immune response showed a male-bias pattern associated with the regulation of protein processing and complement activation of classical pathway. A list of DEGs associated with variant responses to influenza vaccination between females and males were identified by biology-driven clustering. Old females have a greater immune response to QIVs but a rapid antibody decline, while old males have the advantages to sustain a durable response. In addition, we identified genes that may contribute to the sex variations toward influenza vaccination in the aged. Our findings highlight the importance of developing personalized seasonal influenza vaccines.
Collapse
Affiliation(s)
- Jing Yang
- National Institute of Engineering Technology Research in Combination Vaccine, Wuhan 430207, Hubei Province, China.,Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, Hubei Province, China
| | - Xiaoyuan Huang
- National Institute of Engineering Technology Research in Combination Vaccine, Wuhan 430207, Hubei Province, China.,Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, Hubei Province, China
| | - Jiayou Zhang
- National Institute of Engineering Technology Research in Combination Vaccine, Wuhan 430207, Hubei Province, China.,Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, Hubei Province, China
| | - Renfeng Fan
- Guangdong Province Institute of Biological Products and Materia Medica, Guangzhou 510440, Guangdong Province, China
| | - Wei Zhao
- National Institute of Engineering Technology Research in Combination Vaccine, Wuhan 430207, Hubei Province, China.,Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, Hubei Province, China
| | - Tian Han
- National Institute of Engineering Technology Research in Combination Vaccine, Wuhan 430207, Hubei Province, China.,Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, Hubei Province, China
| | - Kai Duan
- National Institute of Engineering Technology Research in Combination Vaccine, Wuhan 430207, Hubei Province, China.,Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, Hubei Province, China
| | - Xinguo Li
- National Institute of Engineering Technology Research in Combination Vaccine, Wuhan 430207, Hubei Province, China.,Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, Hubei Province, China
| | - Peiyu Zeng
- Gaozhou Center for Disease Control and Prevention, Maoming 525200, Guangdong Province, China
| | - Jinglong Deng
- Gaozhou Center for Disease Control and Prevention, Maoming 525200, Guangdong Province, China
| | - Jikai Zhang
- Guangdong Province Institute of Biological Products and Materia Medica, Guangzhou 510440, Guangdong Province, China
| | - Xiaoming Yang
- National Institute of Engineering Technology Research in Combination Vaccine, Wuhan 430207, Hubei Province, China.,China Biotechnology Co., Ltd., Peking 100029, China
| |
Collapse
|
48
|
Leung K, Jaberi A, Kachura J, Duan K, Wong D. A228 WHEN ASCITES & VARICEAL BLEEDING ARE NOT FROM CIRRHOSIS: A CASE OF MUTIPLE ARTERIOPORTAL FISTULAE CAUSING PORTAL HYPERTENSION. J Can Assoc Gastroenterol 2021. [DOI: 10.1093/jcag/gwab002.226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Portal hypertension is usually due to increased resistance from cirrhosis. However, pressures can also be elevated due to increased flow.
Aims
To describe a peculiar case of non-cirrhotic portal hypertension.
Methods
A case report and literature review was performed.
Results
A 47-year-old previously well man presented with a 6 month history of rapidly progressive weight loss, ascites and variceal bleed. Workup ruled out common causes of primary liver disease. Initial imaging demonstrated a heterogenous liver, splenomegaly, ascites, patent hepatic/portal veins and multiple poorly defined low-density hepatic lesions with the largest measuring 2.1 cm. Transient elastography was 7.3 kPa (F1-mild fibrosis). At transjugular liver biopsy, hepatic venogram ruled out Budd-Chiari and hepatic vein pressure gradient was normal at 3–4 mmHg. Histology unfortunately showed hemangioma. A percutaneous liver biopsy suggested nodular regenerative hyperplasia, minimal fibrosis and mild cholestasis. Given worsening ascites, hyponatremia and 7 months of rapidly progressive decline, transjugular intrahepatic portosystemic shunt (TIPSS) was inserted. Intra-procedure, portal vein pressure was noted to be 51 mmHg, with a portosystemic gradient of 42 mmHg. Although numerous abdominal CT and MRI did not show AV shunting, ultrasound post-TIPSS showed hepatic pseudoaneurysms & arterioportal fistulae (APF). Direct angiogram showed numerous hepatic pseudoaneurysms and intrahepatic fistulae making embolization impossible. CT showed no evidence of pseudoaneurysms or fistulae outside of the liver. Workup for autoimmune rheumatological diseases and congenital telangiectatic syndromes were negative. Given the high pressures being directed through the new TIPSS, right heart failure is an ongoing concern.
APF are rarely encountered causes of presinusoidal portal hypertension, with communications most commonly arising from the hepatic (65%) & splenic arteries (11%) & the portal vein. Causes include traumatic (28%), iatrogenic (16%), vascular/telangiectatic malformations (15%), tumors (15%), aneurysms (14%) & congenital disease. Endovascular embolization can be used to treat single lesions. In complex cases with mulitple APF, surgery and/or liver transplantation may be required.
Conclusions
We report a rare case of non-cirrhotic portal hypertension due to increased flow rather than increased resistance secondary to APF.
Funding Agencies
None
Collapse
Affiliation(s)
- K Leung
- University of Toronto, Toronto, ON, Canada
| | - A Jaberi
- University of Toronto, Toronto, ON, Canada
| | - J Kachura
- University of Toronto, Toronto, ON, Canada
| | - K Duan
- University of Toronto, Toronto, ON, Canada
| | - D Wong
- University of Toronto, Toronto, ON, Canada
| |
Collapse
|
49
|
Su CK, Liu CM, Meng X, Hua ZD, Duan K. Rapid Qualitative and Quantitative Analysis of Caffeine and Sodium Benzoate in Annaca by Infrared Spectroscopy. Fa Yi Xue Za Zhi 2021; 37:33-37. [PMID: 33780182 DOI: 10.12116/j.issn.1004-5619.2019.390901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Indexed: 06/12/2023]
Abstract
Objective To establish an infrared spectroscopic method for the rapid qualitative and quantitative analysis of caffeine and sodium benzoate in Annaka samples. Methods Qualitative and quantitative modeling samples were prepared by mixing high-purity caffeine and sodium benzoate. The characteristic absorption peaks of caffeine and sodium benzoate in Annaka samples were determined by analyzing the infrared spectra of the mixed samples. The quantitative model of infrared spectra was established by partial least squares (PLS). Results By analyzing the infrared spectra of 17 mixed samples of caffeine and sodium benzoate (the purity of caffeine ranges from 10% to 80%), the characteristic absorption peaks for caffeine were determined to be 1 698, 1 650, 1 237, 972, 743, and 609 cm-1. The characteristic absorption peaks for sodium benzoate were 1 596, 1 548, 1 406, 845, 708 and 679 cm-1. When the detection of all characteristic absorption peaks was the positive identification criteria, the positive detection rate of caffeine and sodium benzoate in 48 seized Annaka samples was 100%. The linear range of PLS quantitative model for caffeine was 10%-80%, the coefficient of determination ( R2) was 99.9%, the root mean square error of cross validation (RMSECV) was 0.68%, and the root mean square error of prediction (RMSEP) was 0.91%; the linear range of PLS quantitative model for sodium benzoate was 20%-90%, the R2 was 99.9%, the RMSECV was 0.91% and the RMSEP was 1.11%. The results of paired sample t test showed that the differences between the results of high performance liquid chromatography method and infrared spectroscopy method had no statistical significance. The established infrared quantitative method was used to analyze 48 seized Annaka samples, the purity of caffeine was 27.6%-63.1%, and that of sodium benzoate was 36.9%-72.3%. Conclusion The rapid qualitative and quantitative analysis of caffeine and sodium benzoate in Annaka samples by infrared spectroscopy method could improve identification efficiency and reduce determination cost.
Collapse
Affiliation(s)
- C K Su
- Ordos Public Security Bureau, Ordos 017000, Inner Mongolia Autonomous Region, China
| | - C M Liu
- Key Laboratory of Drug Monitoring and Control, Drug Intelligence and Forensic Center, the Ministry of Public Security of the People's Republic of China, Beijing 100193, China
| | - X Meng
- Key Laboratory of Drug Monitoring and Control, Drug Intelligence and Forensic Center, the Ministry of Public Security of the People's Republic of China, Beijing 100193, China
| | - Z D Hua
- Key Laboratory of Drug Monitoring and Control, Drug Intelligence and Forensic Center, the Ministry of Public Security of the People's Republic of China, Beijing 100193, China
| | - K Duan
- Ordos Public Security Bureau, Ordos 017000, Inner Mongolia Autonomous Region, China
| |
Collapse
|
50
|
Wang ZJ, Zhang HJ, Lu J, Xu KW, Peng C, Guo J, Gao XX, Wan X, Wang WH, Shan C, Zhang SC, Wu J, Yang AN, Zhu Y, Xiao A, Zhang L, Fu L, Si HR, Cai Q, Yang XL, You L, Zhou YP, Liu J, Pang DQ, Jin WP, Zhang XY, Meng SL, Sun YX, Desselberger U, Wang JZ, Li XG, Duan K, Li CG, Xu M, Shi ZL, Yuan ZM, Yang XM, Shen S. Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models. Emerg Microbes Infect 2021; 9:2606-2618. [PMID: 33241728 PMCID: PMC7733911 DOI: 10.1080/22221751.2020.1852059] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
The ongoing COVID-19 pandemic is causing huge impact on health, life, and global economy, which is characterized by rapid spreading of SARS-CoV-2, high number of confirmed cases and a fatality/case rate worldwide reported by WHO. The most effective intervention measure will be to develop safe and effective vaccines to protect the population from the disease and limit the spread of the virus. An inactivated, whole virus vaccine candidate of SARS-CoV-2 has been developed by Wuhan Institute of Biological Products and Wuhan Institute of Virology. The low toxicity, immunogenicity, and immune persistence were investigated in preclinical studies using seven different species of animals. The results showed that the vaccine candidate was well tolerated and stimulated high levels of specific IgG and neutralizing antibodies. Low or no toxicity in three species of animals was also demonstrated in preclinical study of the vaccine candidate. Biochemical analysis of structural proteins and purity analysis were performed. The inactivated, whole virion vaccine was characterized with safe double-inactivation, no use of DNases and high purity. Dosages, boosting times, adjuvants, and immunization schedules were shown to be important for stimulating a strong humoral immune response in animals tested. Preliminary observation in ongoing phase I and II clinical trials of the vaccine candidate in Wuzhi County, Henan Province, showed that the vaccine is well tolerant. The results were characterized by very low proportion and low degree of side effects, high levels of neutralizing antibodies, and seroconversion. These results consistent with the results obtained from preclinical data on the safety.
Collapse
Affiliation(s)
- Ze-Jun Wang
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, People's Republic of China
| | - Hua-Jun Zhang
- Center for Biosafety Mega-Science, Chinese Academy of Sciences, CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Wuhan, People's Republic of China
| | - Jia Lu
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, People's Republic of China
| | - Kang-Wei Xu
- National Institutes for Food and Drug Control, Beijing, People's Republic of China
| | - Cheng Peng
- Center for Biosafety Mega-Science, Chinese Academy of Sciences, CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Wuhan, People's Republic of China
| | - Jing Guo
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, People's Republic of China
| | - Xiao-Xiao Gao
- Center for Biosafety Mega-Science, Chinese Academy of Sciences, CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Wuhan, People's Republic of China
| | - Xin Wan
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, People's Republic of China
| | - Wen-Hui Wang
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, People's Republic of China
| | - Chao Shan
- Center for Biosafety Mega-Science, Chinese Academy of Sciences, CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Wuhan, People's Republic of China
| | - Su-Cai Zhang
- JOINN Laboratories (Beijing), Beijing, People's Republic of China
| | - Jie Wu
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, People's Republic of China
| | - An-Na Yang
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, People's Republic of China
| | - Yan Zhu
- Center for Biosafety Mega-Science, Chinese Academy of Sciences, CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Wuhan, People's Republic of China
| | - Ao Xiao
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, People's Republic of China
| | - Lei Zhang
- Center for Biosafety Mega-Science, Chinese Academy of Sciences, CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Wuhan, People's Republic of China
| | - Lie Fu
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, People's Republic of China
| | - Hao-Rui Si
- Center for Biosafety Mega-Science, Chinese Academy of Sciences, CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Wuhan, People's Republic of China
| | - Qian Cai
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, People's Republic of China
| | - Xing-Lou Yang
- Center for Biosafety Mega-Science, Chinese Academy of Sciences, CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Wuhan, People's Republic of China
| | - Lei You
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, People's Republic of China
| | - Yan-Ping Zhou
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, People's Republic of China
| | - Jing Liu
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, People's Republic of China
| | - De-Qing Pang
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, People's Republic of China
| | - Wei-Ping Jin
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, People's Republic of China
| | - Xiao-Yu Zhang
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, People's Republic of China
| | - Sheng-Li Meng
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, People's Republic of China
| | - Yun-Xia Sun
- JOINN Laboratories (Beijing), Beijing, People's Republic of China
| | - Ulrich Desselberger
- Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
| | - Jun-Zhi Wang
- National Institutes for Food and Drug Control, Beijing, People's Republic of China
| | - Xin-Guo Li
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, People's Republic of China
| | - Kai Duan
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, People's Republic of China
| | - Chang-Gui Li
- National Institutes for Food and Drug Control, Beijing, People's Republic of China
| | - Miao Xu
- National Institutes for Food and Drug Control, Beijing, People's Republic of China
| | - Zheng-Li Shi
- Center for Biosafety Mega-Science, Chinese Academy of Sciences, CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Wuhan, People's Republic of China
| | - Zhi-Ming Yuan
- Center for Biosafety Mega-Science, Chinese Academy of Sciences, CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Wuhan, People's Republic of China
| | - Xiao-Ming Yang
- National Engineering Technology Research Center of Combined Vaccines, Wuhan, People's Republic of China.,China National Biotec Group Company Ltd, Beijing, People's Republic of China
| | - Shuo Shen
- Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.,National Engineering Technology Research Center of Combined Vaccines, Wuhan, People's Republic of China
| |
Collapse
|